Report of the fourteenth session of the Joint Action Forum

JOINT ACTION FORUM Office of the Chairman JAF-FAC: FIFTEENTH SESSION Tunis, 8 - 10 Decemberr 2009 FORUM D'ACTION COMMUNE Bureau du Pr6sident African Programme for Onchocerciasis Control Programme africain de lutte contre l'onchocercose REPORT OF THE FOURTEENTH SESSION OF THE JOINT ACTION FORUM I JAF I5.4 ORIGINAL: ENGLISH September 2009 0 fTable of Content Acronyms Opening of meeting Election of officers Testimonies Film on onchocerciasis vector control activities Adoption of agenda Reflections of the Committee of Sponsoring Agencies (CSA) WHO progress report.......... Statements by Ministers of Health.. Treatment Coverage: Presentation by Representatives of Countries Training: Presentation by Representatives of Countries Government Contributions ............. Outcome of the closed-door sessions ............... Report of the NGDO Coordination Group for Onchocerciasis Control Report of the Technical Consultative Committee (TCC) Sustainability of CDTI by Governments: review of implementation of plans . Elimination of Transmission of Onchocerciasis in Africa..... Recommendations of the Uganda Onchocerciasis Elimination (UOEC) ......... Report of the final evaluation of the (SIZ) of former OCP countries............... Research on MACROFIL ............. Health Impact Assessment of APOC operations Audit Report................ Addendum to Plan of Action and Budget 2008 - 2015........... PIan of Action and Budget for 2009 Financing of the African Programme for Onchocerciasis Control (APOC)..... Donor Pledges Activities in ex-OCP countries.... Activities of the Multi-Disease Surveillance Centre (MDSC) Other matters ............... Date and place of JAFl5 ............... Review of Final Communiqu6................. Closure of the fourteenth JAF Session Annexes.. JAFI5.4 Page i ...11 ... I ...2 ...2 ... J ,.. 3 ...3 ...3 ...4 ...6 ...7 ...7 ... 8 ...9 ...9 .10 .10 .11 .11 t2 t2 l3 13 13 13 13 l4 15 15 15 15 t6 JAFI5.4 Page ii Acronyms APOC AU CAR CDDs CDI CDTI CMFL CSA DALYs DRC IDPS JAF LF MDA MDGs MDP MDSC MEC MOU NEPAD NGDO NTDs OCP PAB SAEs STZ SSI STH TCC TDR USAID WAHO wHo African Programme for Onchocerciasis Control African Union Central African Republic Community Directed Distributors Community Directed lntervention Community Directed Treatment with Ivermectin Community microfilarial load Committee of Sponsoring Agencies Disability Adjusted Life Years Democratic Republic of Congo Internally Displaced persons Joint Action Forum Lymphatic Filiariasis Mass Drug Administration Millennium Development Goals Mectizan Donation Programme Multi-Disease Surveil lance Centre Mectizan Expert Committee/Albendazole Coordination Memorandum of Understanding New Partnership for African Development Non-Governmental Development Organization Neglected Tropical Diseases Onchocerciasis Control Programme Plan of Action and Budget Serious Adverse Events Special Intervention Zones Sight Savers International Soil Transmitted Helminth Technical Consultative Committee Special Programme for Research and Training in Tropical Diseases United States Agency for International Development West Africa Health Organization World Health Or ganization t t_ JAFI5.4 Page I Opening of meeting l. The Fourteenth Session of the Joint Action Forum (JAF) of the African Progtamme for Onchocerciasis Control (APOC) was hosted by the Republic of Uganda, from 8 to 1l December 2008 in Kampala, Uganda. The meeting was attendedby 7 Honourable Ministers and Deputy Ministers of Health of APOC and OCP countries, Permanent Secretaries and Directors of Health and Disease Control, I I representatives of the donor community, the World Bank, the WHO, including APOC management, ihe West African Health Organization (WAHO), Non-Governmental Development Orgariizations (NGDOs), the Mectizan Donation Programme, Merck & Co' [nc', Wyeth Pharmaceuticals, Research Institutions, Directors and Coordinators of National Onchocerciasis Control Programmes, Onchocerciasis Endemic District Management Leaders of Uganda and Representatives of the Statutory Bodies of APOC. A complete list of participants is appended as Annex l. 2. Mrs Mary Nannono, Permanent Secretary, Ministry of Health, Uganda, handled the protocol for the opening session. 3. His Excellency, the President of the Republic of Uganda, President Yoweri Museveni, officially opened the meeting. In his speech, President Museveni, welcomed participants and thanked JAF foi choosing Uganda to host its l4th session. Uganda like other developing countries was afflicted by many Ntbs. He highlighted Uganda's successes in public health with special mention of the elimination of Guinea woffn and control of Sleeping Sickness in both humans and cattle. The Carter Center was thanked for their efforts as a partner in the elimination of Guinea worrn. Uganda has both the political and technical commitment, needed to extend the same kind of success to the elimination of onchocerciasis, lymphatic filiariasis and other NTDs. Given the direct and indirect link between health and agriculture to the attainment of the MDGs, President Museveni stressed that without addressing the NTDs, Africa will not be able to achieve the MDGs. Merck and Co', Inc were thanked for the donation of ivermectin, without which it would be impossible to control or eliminate onchocerciasis in African countries and particularly in Uganda. 4. Dr Saweka, the World Health Organization representative, read a speech on behalf of Dr Margaret Chan, Director-General of the World Health Organization. Dr Chan expressed gratitude to the government of Uganda for hosting the meeting. She attributed the success of the programme to sustained political will from affected member states, excellent collaboration between the different levels of government and affected communities, and the hard work and sfiong team spirit of health- care workers and particularly the affected communities. She acknowledged the invaluable contributions from the NGOs and thanked Merck and Co., [nc. for both the ivermectin donation and financial contribution to APOC. 5. Dr Chan urged African governments to safeguard the gains achieved in onchocerciaisis control and continue reducing the impact of the disease as a pressing public health problem and an impediment to socio-economic development. Lastly, she welcomed APOC's paradigm shift in 2007 from a single to multiple disease focus and the use of CDTI to deliver multiple health interventions and commodities to onchocerciais-endemic, hard -to-reach populations. 6. Dr Stephen Mallinga, Minister of Health, Uganda, informed the forum that onchocerciasis was prevalent in 27 districts in Uganda, where more than 2.5 million people were at risk of infection and more than I million people were already infected with the disease. He thanked the donors for their efforts in bringing down the prevalence of the disease from 70o/o in 1993, to the cunent 7o/o. Uganda has embarked on a mission to eradicate onchocerciasis through semi-annual treatment with ivermectin plus vector elimination. Vector elimination started in 1995 to supplement ivermectin treatment in 6 districts (Kabarole, Kyenjojo, Kibaale, Ibanda, Kamwenge and Bushenyi), and is ongoing in Mbale, Sironko, Bududa and Manafira.In2009, vector elimination will be extended to JAFI5.4 Page 2 Hoima, Bullisa, Masindi, Kabale, Kisoro and Kanungu. Vector elimination had been achieved in three foci (Itwara, Mpamba-Nkusi and Mt. Elgon) and was nearly achieved in Kashoya-Kitomi focus. 7. Dr Mallinga said that Uganda had for the past l0 years maintained treatment coverage at more than 70%o and that the goal was to eliminate onchocerciasis in the country by 2015. Due to the global interest for integrated control of NTDs, Uganda in partnership with development partners including APOC had already started integrated mass drug administration using CDTVschool-based approaches to control these diseases, with promising results. He therefore urged donors of APOC to support APOC to pursue the strategy of integrated control of NTDs in Africa. 8. Dr Uche Amazigo, APOC Director who also represented the WHO Regional Director for Africa, Dr Luis Gomes Sambo, thanked His Excellency, the President of the Republic of Uganda, for honouring the meeting with his presence, and thanked the government of Uganda for hosting JAF14. She emphasised the historic nature of JAFI4, because for the first time in the 33 years of river blindness control in Africa, and 2l years of the unique donation of the drug, Mectizan@ by Merck and Co. Inc., the meeting would receive scientific evidence of elimination of river blindness transmission in Mali, Senegal and most recently in Kaduna state, Nigeria using ivermectin treatment alone delivered by African communities themselves - a proof that community directed intervention is efficient if fully supported by the health systems. The meeting would also receive information on the elimination of river blindness transmission in Uganda through vector control. 9. Dr Amazigo, requested His Excellency, President Museveni, to bring to the attention of the African Union's New Partnership for African Development (NEPAD) and other heads of state, the importance of the river blindness control activities, a key strategic direction of the health service delivery to assist Africa achieve the Millennium Development Goals (MDGs). However, despite the successes, the battle against river blindness is not completely won and the leadership and commitment of African highest level of governments are now more than ever critical for sustaining river blindness elimination activities. Without AIJ's commitment to finish this battle against river blindness, Africa will definitely lose some of its hard won gains. Lastly, Dr Amazigo, requested President Museveni to bring to the attention of the AU, and also appeal to drug manufacturers, for a free donation of Praziquantel for the treatment of thousands of African children suffering from bilharzia. 10. Dr Dani Ceuninck, outgoing Chair JAFI3, highlighted the key achievements of 2008. Progress had been recorded by partners in various areas including; the improvement of demarcation of onchocerciasis areas through REMO in i08 villages in Angola and97 villages in Mozambique; the integrated mapping of five NTDs in Equatorial Guinea with the assistance of partners (Exxon Mobil, University George Washington and the Liverpool School of Tropical Medicine); the expansion of CDTI, with an increase of 12.5%o people treated compare to 2006 figures; the preparation of the Addendum to the Strategic Plan 2008-2015 and the devolution of activities and transfer of responsibilities to governments and local partners in preparation for APOC's exit. Some challenges encountered in 2008 related to conflicts, socio-political unrest and co-endemicity of onchocerciasis and Loa loo,btt these were successfully tackled by partners. Despite these successes, some concerns remained and Dr Ceuninck called upon donors and partners to assist countries to put in place coordinated integrated policies for onchocerciasis control and multiple health interventions. Election of officers 1 1. JAF nominated the Government of the Republic of Uganda, in the person of Dr. Mallinga as Chair of JAFl4 and The African Development of Bank as Vice-Chair, in the person of Dr. Diop-Ly. Testimonies 12. Three members of onchocerciasis endemic communities in Uganda gave testimonies on the debilitating effects and the socio-economic burden associated with the disease, and how ivermectin had been effective in reversing their suffering from onchocerciasis. I JAF15.4 Page 3 Film on onchocerciasis vector control activities 13. A video film was shown on the success of onchocerciasis vector control activities in Uganda and Equatorial Guinea, with the support of APOC and partners as well as the active participation of governments of the two countries and national NGDOs. Adoption of agenda 14. The provisional agenda appended as Annex 2 was adopted without any amendments Reflections of the Committee of Sponsoring Agencies (CSA) 15. The reflections of the Committee of Sponsoring Agencies (CSA) were presented by Dr Chris Mwikisa, Chairman of the Committee. The main activities of the CSA and the programme during 2008 included taking stock of the deliberations of JAFl3, developing the Addendum to the Strategic Plan of action 2008-2015, finalizing agreements with donors willing to provide financial support through the Trust Fund, assessing the results achieved by the Special Intervention Zones (SIZ) and closure of the Onchocerciasis Control Programme (OCP). The committee also reflected on the strategic and operational implications of the results of two major studies conducted by TDR on how and when to stop ivermectin treatment, the use of CDTI strategy for co-implementation and health systems strengthening, as well as support to be provided to some former OCP countries such as Ghana, where post-SIZ evaluation has shown less satisfactory results than expected. 16. The CSA stressed the need for governments to make multi-year commitments to onchocerciasis control and surveillance. The committee also informed JAF that it had accepted the suggestion that the African Development Bank become a co-sponsor of the APOC programme. The CSA also agreed that UNICEF should be invited to become a co-sponsor. The Memorandum of Understanding is therefore to be amended accordingly and will be submitted to JAFI5 for adoption. WHO progress report ll. lntroducing presentations on the progress report of APOC, the Director of the Programme thanked JAF for the expanded mandate granted APOC in 2007, which had presented the countries with both opportunities and challenges. 18. Progress had been made in the mapping of onchocerciasis endemicity. To date, 11 000 communities had been mapped using the following methods: fuEMO/fuEA was completed in Mozambique and Angola in 2007 with activities ongoing in Sudan, CAR and Uganda and pending in some provinces in DRC. RAPLOA was completed in Angola in 2008 and on-going in Sudan. Integrated mapping of oncho, LF, Schisto and STH was completed in Equatorial-Guinea in 2008. Findings from the mapping of LF and onchocerciasis where the two diseases overlap revealed that in Tanzania,3 million people would require dual treatment, whilst the figure for Malawi was 2.5 million people. 19. Fifty-five million people were treated in2007 and the programme recruited technical advisors for Angola, CAR, DRC, Liberia and Sudan in 2008. To enhance efficiency, key M&E activities were carried out and were on-going on independent participatory monitoring, sustainability evaluation and the implementation of sustainability plans. The JAF commended the management of APOC for the WHO Progress Report. 20. In 2008, APOC management participated in two meetings on integration: the "lnternational Conference on Primary Health Care and health systems in Africa" (Ouagadougou) and the "Integration of onchocerciasis controls into health system:Multi partners meeting" (Addis Ababa). One of the identified key challenges of co-implementation was the absence of a government policy, JAF15.4 Page 4 and APOC management requested JAFl4 to provide guidance on the development of a global policy on co-implementation. 21. Studies on cessation of ivermectin treatment were ongoing in Kaduna state in Nigeria, Mali and Senegal and a study on onchocerciasis transmission was being conducted in Uganda. Preliminary findings from all the studies would be shared with JAF14. 22. Following the recommendation of JAFl3, APOC prepared the Addendum to PAB 2008- 2015, which included the following key components: support to post- conflict countries, co- implementation, where and when to stop ivermectin treatment, mainstreaming gender and the strengthening of APOC management. APOC in preparation of its exit, will focus on ensuring that governments fulfilled their financial responsibility on onchocerciasis control and the cessation of APOC operations without jeopardizing past achievements of OCP and APOC. Statements by Ministers of Health 23. The following countries delivered statements to the JAF: Honourable Minister A. Mama Fouda (Cameroon), Honourable Minister David Mwakyusa (Tanzania); Honourable Minister Tabita Shokai (Sudan); Honourable Minister Mariame Beavogui (Guinea), Honourable Minister of State Emmanuel Otala (Uganda), Honourable Minister W. Gwenigale (Liberia), Honourable Vice Minister M. V. Ndongo Asue (Equatorial Guinea). Ministers of the following countries were represented by either Permanent Secretaries, Directors of Programme or Directors of Disease Control: Burkina Faso, Chad, Ghana, Malawi, Benin, DRC, Ethiopia, Nigeria and Togo. a) Benin: A programme on the co-implementation of NTDs had been developed in2007 and an annual budget of CFA 370 million allocated to these activities. Although two vehicles had been purchased for the supervision of NTD programmes, additional financial suppoft was requested from donors for control activities. An urgent challenge for the country was to find a way of re-employing former SIZ personnel under the country's health system. b) Burkina Faso: The geographical coverage remained at l00Yo and the therapeutic coverage at 8002. However, an epidemiological evaluation conducted in 2008, in a focus along the Togo - Cote d'Ivoire border showed a prevalence level of more than 5%o, hence the need for surveillance activities to avoid recrudescence. An amount of approximately US$ 400, 000 was included in the national budget for onchocerciasis activities and the control of other NTDs. The country had begun the integration of NTDs (onchocerciasis, LF, Trachoma, Schistosomiasis and intestinal worms) in 2006, with financial help from USAID and other partners. c) Cameroon: An appeal was made to APOC to provide financial and technical supporl to CDTI projects in the East, Littoral and Southern zones up to2015. Onchocerciasis remains the third cause of blindness in Cameroon, and in some districts the disease is co-endemic with Loa loa. The country also has a high prevalence of Severe Adverse Events (SAEs). To demonstrate its commitment to onchocerciasis control, the government had in 2008, allocated the sum of US$857,000 to CDTI activities, out of which US$658,000 had been disbursed. d) Chad: More than 1.8 million people are exposed to onchocerciasis in some 3250 villages. Although therapeutic coverage ryas above 800%, there were still problems with refugees and more assistance was requested from external partners, local actors and APOC. The country has carried out a population census, and the control of NTDs and co-implementation activities were now integrated into the national health system. A national strategy on poverty alleviation has been developed, and a plea was made to the donor community for continued support of the CDTI in Chad. JAF15.4 Page 5 e) Democratic Republic of Congo: The forum noted that DRC was going through a diffrcult humanitarian crisis, and a plea was made to partners to maintain support for uninterrupted onchocerciasis control until victory was achieved against the disease. Epidemiological mapping showed that onchocerciasis was prevalent in all districts of the country with: 23,698,000 persons at risk, 14,000,000 infected persons and 10,000 people already blind. In the country Twenty of the 2l CDTI projects were being implemented, with 14 or 70%o of the ongoing projects facing the risk of SAEs. f) Ethiopia: Treatment coverage had improved and the country was working closely with APOC on an integration approach that would be sustainable by the health systems after the cessation of external support. The same strategy would be used for other NTDs. g) Equatorial Guinea: Remarkable achievements had been made in vector elimination in the Bioko focus. The elimination activities which started in 2002 were completed in 2005. The government has reaffirmed its political commitment by allocating the equivalent of US$ 280, 000 to the control of onchocerciasis and other NTDs in 2009. The WHO, World Bank, APOC and the NGDOs were commended for their continued support. h) Ghana: A review meeting with the support of SSI, was held in 2008, and onchocerciasis has now been moved from under the health research unit to the disease control unit of the Health Ministry, to ensure better collaboration of health activities. The review identified some gaps, and APOC was requested to provide support to address these gaps. Ghana has also drawn up a comprehensive plan of action for all NTDs, results of which will be shared with partners during a stakeholders' meeting to be held in the country in2009. i) Guinea: A total of 38 905 500 Mectizan tablets were used to treat 2 million people annually from 2003-2007. Merck and Co. Inc., and MDP were thanked for the donation and a recommendation was made to the government of Guinea to continue with the release of national funds for CDTI and epidemiological surveillance. The evaluation of the SZ in 2008 provided encouraging results, however, partners were requested to provide support in order to monitor the transmission foci along the countqr's border with Sierra Leone, Liberia, Cote d'Ivoire and Guinea-Bissau, where social unrest had led to irregularities in treatment. j) Liberia: In November 2008, the NOTF conducted an internal participatory monitoring in 9 CDTI projects. Some key priorities for 2009 include; CDTI training of at least 60oh health staff; strengthening of the NOTF's functions to improve CDTI implementation and the promotion of co-implementation of CDTI and other health programmes. k) Malawi: Malawi has maintained a therapeutic coverage of more than 65%o and 100% geographical coverage. MDA for onchocerciasis and LF was carried out in 2008, and there were plans to take on board other health interventions. In November 2008, the Ministry of Health intensified efforts to raise public awareness of onchocerciasis. The donor community was commended for their support and requested to sustain the support in order to win the war against onchocerciasis. l) Nigeria: [n Nigeria, 413 out of the 744local government areas in 36 states and the Federal Capital Territory are benefiting from CDTI. An estimated 30 million people in about 36,000 communities are at risk and need to be treated every year for 25 years. LF mapping has been completed in the northeast and northwest zones, and Schistosomiasis in a few states, in preparation for MDA. However, Loa loa was still a major threat in the South and some parts of the Southeast zones of the country. m) Sudan: APOC was thanked for deploying Technical Advisor to support Southern Sudan's CDTI projects in 2008. Sudan, being a post-conflict country with increased population in some areas due to returnee IDPs and weak health systems, an appeal was made to APOC and JAFI5.4 Page 6 the donor community to continue support to the country well beyond the 5 to 8 years set limit. More assistance was also requested from the APOC secretariat for the conduct of a study on a new emerging "nodding disease." Lastly, JAF was informed that the administration of the CDTI programme in North Sudan had been relocated to the FMoH premises, while the Ministry with the assistance of the Carter Center, had recruited additional technical staff to the programme with emphasis on M&E, to guide scientific work. n) Tanzania: Therapeutic coverage had remained above 75o/o and geographical coverage at 100%. ln the financial year 200819, the government allocated Tanzanian shillings 165, 860,000 for onchocerciasis control at the central level. With support from APOC, the country has conducted an evaluation of sustainability in Tunduru and Morogoro CDTI projects. JAF was informed that in 2007, MDA for LF was combined with the onchocerciasis programme using the CDTI strategy in Morogoro region, with encouraging results. But inadequate funding was cited as a challenge and an appeal was made to APOC and donors to provide more financial, technical and material support to the country. o) Togo: The country has achieved a geographical coverage of 95-l00Yo and a therapeutic coverage of 80-85%. A meeting on cross-boder issues is to be held with Ghana in 2009 to discuss endemicity along their common borders. APOC, SSI, MDP, OCP and WHO/AFRO were commended for their support and encouragement. p) Uganda: The country's representative announced that prevalence had dropped from 70% in 1993 to 7%o in 2008. He reiterated the statement from the Minister of Health that Uganda's new strategy was that of elimination of onchocerciasis through semi-annual treatments with ivermectin plus vector control. 24. After the ministerial statements and a discussion at the plenary, the following issues were highlighted: a) To address the challenges of Severe Adverse Events (SAEs), particularly in response to Cameroon's request for assistance, the JAF called for close collaboration among the affected countries, particularly Cameroon and DRC for joint research into the prevention and management of SAEs. Cameroon was requested to develop a national strategic plan with an investment component to be presented to partners and donors. The strategic plan will then be reviewedtogetherwithanepidemiologicalstudyin2010 -2011, todetermineanynecessary future activities. b) The JAF assured governments, especially those from conflict and post-conflict countries that the stopping of MDA was possible after 18 years, however, it noted that this would require the determination of governments. The JAF therefore recommended that countries speed up the processes of empowering and training communities, maintaining therapeutic coverage of 7lyo+ and building partnerships with communities. Treatment coverage: presentation by representatives of countries 25. [n2007, APOC achieved a geographical coverage of 89.'7%o and a therapeutic coverage of 67.60A, which translated to 54.6 million people treated. Cameroon, Ethiopia, Malawi, Nigeria, Tanzania and Uganda maintained a therapeutic coverage of 65%o. Congo, Chad, Liberia and Equatorial Guinea, made tremendous progress towards reaching the threshold, whilst Sudan, CAR, DRC and Angola were yet to reach 65%o therapeutic coverage. Geographical coverage was impressive in post-conflict countries, with Chad and Burundi both maintaining 100% coverage in 2007, while Angola's geographical coverage was above 90%. Nigeria, Ethiopia, Cameroon, Congo, Equatorial Guinea, Malawi, Tanzania and Uganda, all maintained over 90%o geographical coverage. [t was also noted that health interventions co-implemented with CDTI covered 10,737,298 people in2007. JAFI5.4 Page 7 Training: Presentation by Representatives of Countries 26. Between 2005 and 2007, the number of CDDs trained had doubled, with 337,753 CDDs trained and retrained to date. It was noted that NOTFs usually trained 10 times more CDDs than health workers, who had limited time for CDTI training due to heavy workloads. Countries were encouraged to acknowledge the enorrnous contributions of CDDs to health systems and to fund the training of CDDs to reach the threshold ratio of I CDD: 100 total population. It was noted that out of the l9 APOC countries only Ethiopia and Uganda had attained this ratio. Cross-Corder Collaboration 27. Following the presentations on treatment and training, the JAF expressed concern over the negative impact on treatment coverage caused by cross-border issues. The countries pledged to finance cross-border meetings and requested support from APOC, which was approved by the JAF. Governments' Contributions 28. In 200'1, overall government contributions in support of CDTI activities, (equipment and salaries) amounted to US$ 25, 617 ,l2l million, an 8 times' increase from the 2003 figures. Out of this amount, US$ I .5 million was invested at the national level; US$ 2.2 million at the regional and US$ 22 million at the district/sub district level. An amount of US$ l, 888, 513 was disbursed by the programme in 2007, to thirteen countries to fund k"y CDTI activities: mobilisation/sensitization/health education of communities, advocacy, training, supervision/monitoring and ivermectin distribution. Overall, countries are making efforts to document governments' financial contributions from national budgets to onchocerciasis contry; but on the whole, increased financing is needed to ensure the sustainability of CDTI. 29. The JAF welcomed the increase in governments' financial contributions. However, to safeguard the gains of over 30 years of onchocerciasis control in Africa, the JAF stressed the need for country ownership of CDTI activities as a precondition for sustainability, and as a positive trend of reaffirmation of the countries' commitment to onchocerciasis control. The JAF urged Ministers of Health and programme managers to explore ways of increasing govemments' financial allocation through discussions with officials in charge of national budgets. The African Development Bank and the World Bank were also requested to use their advocacy role to assist onchocerciasis control managers and governments in financial negotiations. Budgeted funds at the country level should be promptly released to projects, especially to coincide with the programme activities timetable. 30. Following the presentation, the following key points were raised in the plenary discussion: a) APOC was requested by JAF to submit to future JAF meetings, detailed breakdown of figures on the proportion of government funding in relation to contributions by APOC and other partners, based on accurate data from countries. The World Bank offered to work with countries in developing scenarios on the funding of CDTI activities. b) The JAF noted the decline of government contribution between 2005 and 2007 in Nigeria which has many CDTI projects. The head of the Nigerian delegation explained that the country faced many health issues competing for limited government resources and reported that there was a slight increase in the 2008 budget allocation to CDTI activities. The JAF commended Nigeria for these effiorts and encouraged the country to mobilise more resources for CDTI activities. Given the huge financial implication of vector control (sustainable funding for l0 years), the difficult terrain and the challenges associated with spraying of the rivers, APOC encouraged Nigeria to concentrate on elimination using ivermectin treatment. JAFI5.4 Page 8 c) The JAF noted that horizontal implementation of programmes posed a challenge to countries on the reporting of onchocerciasis specific budgets. However, countries were encouraged to explore mechanisms for extrapolating the onchocerciasis budgets from the overall budget in order to present more accurate figures. d) APOC management informed JAF that the programme was actively exploring ways of building public-private partnerships with African based corporations for funding opportunities. An invitation to JAF14 was extended to a Chief Executive Officer of a pharmaceutical company in Nigeria, who was able to attend the forum, and also to that of Chevron in Equatorial-Guinea, who unfortunately, was unable to attend. e) The JAF expressed concern over the high percentage of funds allocated to health workers' salaries on the overall budget. While health workers' functions are crucial to the sustainability of onchocerciasis control, other core CDTI activities should not be neglected. Outcome of the closed door sessions 31. Separate closed-door sessions of African Health Ministers, Donors and NGDOs reported the following outcomes: Ministers 32. The Ministers resolved to budget for cross-border collaboration meetings and to set up a ministerial committee which would meet regularly to discuss the management of oncherciasis and other NTDs. Countries were urged to prepare proposals to the Global Fund for support of NTDs control. ln order to increase governments' contributions to the sustainability of CDTI projects, Ministers of Health agreed to work with colleagues in the Finance Ministries of their countries to ensure a steady increase in the allocation and disbursement of funds for onchocerciasis control. Ministers urged conflict and post conflict countries to come up with clear plans indicating areas of need in CDTI project implementation. In light of APOC's exit in 2015, the Ministers committed to prepare their national exit plans with an emphasis on surveillance activities during and post APOC period. An appeal was made to the African Union to request Merck Germany for a donation of praziquantel for the treatment of bilharzia. Donors 33. The contribution of APOC in strengthening primary health care systems was acknowledged and supported, though it was emphasized that the programme should not overstretch its capacity. APOC was encouraged to assist countries in developing exit strategies that indicate the contribution of all parties and that could serve as roadmaps for proper monitoring on an annual basis, as a matter of priority. ln addition, countries should ensure that the budget for onchocerciasis activities was fully integrated into national health plans and thereby benefit from opportunities to obtain funding from donors at national level following changes in policies with some donors. APOC and countries were also encouraged to come up with a gender sensitive approach to increase the female participation in CDTI activities. Donors were happy with the current reporting system for the Trust Fund, however they expressed a need to revisit the issue in the future if necessary, to ensure that some requirements by donors were compatible with the reporting format of APOC. Lastly, it was noted that the increased attention and funding for NTDs called for adequate coordination. The NGDO Group 34. The Group gave its full support to the Addendum and elimination efforts, and encouraged the programme to consider scientific rigour approaches in identifuing when elimination can be achieved, and to develop a definition for 'elimination.' There was also the need to enhance coordination among NGOs among neighbouring countries and to budget for cross-border meetings. The Group urged JAF15.4 Page 9 APOC to work closely with other partners to step up co-implementation of CDTI with other health interventions, especially those targeting NTDs. 35. The outcomes of the closed-door sessions were discussed in the plenary and the following key issues were raised: a) The JAF expressed gratitude to Merck Germany for the assistance with praziquantel, but acknowledged the need for greater access to treatment by be millions of African children suffering from bilharzia. b) To this end, the JAF urged African Ministers to explore local and international ways of obtaining the treatment drug, praziquantel. African pharmaceutical companies were also encouraged to manufacture generic drugs for the treatment of NTDs. A Nigeria-based pharmaceutical company JUDEL, pledged to make available for donation and sale, the drug for the treatment of bilharzia in 2009. c) The JAF encouraged countries to use the model developed by APOC on co-implementation as a template for developing country-specific co-implementation plans, in preparation for APOC's exit. APOC was requested to play an advisory role to the countries by providing them with assistance on developing these plans. Report of the NGDO Coordination Group for Onchocerciasis Control 36. Since September 2008, Schistosomiasis Controllnitiative had become the 14n member of the Group under the new chairmanship of Mr Simon Bush assisted by Mrs Francisca Olamiju as the vice chairperson. Ivermectin mass distribution has been expandedto 13 of the l5 APOC countries where CDTI is being implemented. Chad and Equatorial Guinea are the only APOC countries in need of NGDO support. The Group had supported treatment of a total of 65,982,547 people worldwide in 2007; distributed as follows, 48,193,199 in APOC countries; 15,895,639 in former OCP countries; 843,095 in OEPA countries and 50,164 in Yemen. A total of US$ 12,437,170 was disbursed in 2007 by members of the Group to support ivermectin mass distribution globally, out of which about 50% was allocated to APOC countries. The NGDO Coordination Group for Onchocerciasis Control is committed to CDTI activities and expanding activities towards NTDs control. 37. The report highlighted the NDGO Group's support to countries, as well as challenges in carrying out activities in conflict and post-conflict countries due to the political climate and insufficient resources. The NGDOs reiterated their commitment to onchocerciasis and NTD control. Report of the Technical Consultative Committee (TCC) 38. During 2008, the TCC reviewed 9l annual technical CDTI project reports, 3 Annual NOTF HQ support projects, 3 technical reports from vector elimination projects. The National technical committee of Nigeria reviewed technical reports of 19 projects aged 8 years and above and reported to TCC27 . There was overall improvement in CDTI project implementation and reporting with some exceptions. In stable countries there were delays in implementation, while in conflict and post- conflict countries geographic and therapeutic coverages were generally low. The TCC reviewed 5 neilrevised operational research proposals, approved only 2 and recommended that the existing mechanism for in-country review of operational research proposals, prior to submission to APOC, should be strengthened. 39. The TCC was also assisting countries with the preparation of strategic national exit plans for APOC. Follow-up issues included brief to TCC on TDR proposed research strategy and institutional framework for monitoring of drug efficacy in large scale treatment programmes for onchocerciasis control in Africa. The committee endorsed the proposal, recommended identification of regional JAFI5.4 Page l0 laboratories in Africa to collaborate with the ones in developed countries; and urged APOC to convene a meeting of potential scientists, to discuss and initiate the activity 40. The JAF expressed appreciation for the activity report of the TCC and commended the committee for assisting countries in developing national strategic plans, in preparation for the exit of APOC. These plans which will serve as agreements between governments, APOC and all stakeholders should be submitted to TCC for review and subsequently for the approval of JAF. The monitoring of the implementation of the plans should be reported annually to JAF. Sustainabilify of CDTI by Governments: review of implementation of plans 41. The presentation looked at the challenges and opportunities available to governments and communities in sustaining CDTI activities. For clarity the definition of sustainability was given as: "CDTI activities in an area are sustainable when they continue to function effectively for the foreseeable future with high treatment coverage, integrated into the health care service with strong community ownership using resources mobilised by the community and government." Using this definition, 24 projects were assessed: Cameroon (4), Ethiopia (l), Malawi (2), Nigeria (10), Tanzania (4) and Uganda (3). The findings showed that the majority of the 24 projects assessed performed well and were sustainable at the community level, but sustainability performance was poor at the sub- district level due to weak frontline health facilities (FLHFs). This weakness was attributed to insufficient commitment by governments (central and regional/state) and late release of funding for the implementation of CDTI activities. Elimination of Transmission of Onchocerciasis in Africa 42. Mali, Senegal, Guinea Bissau and Nigeria Study: Impressive findings from studies in these countries presented to JAF, provided scientific evidence of sustained interruption of transmission of onchocerciasis using ivermectin treatment alone, "The question is no longer y' onchocerciasis elimination is possible with ivermectin treatment but rather where and when it can be done". As a follow up to preliminary results presented to JAFl3, updates were presented for each country: a) Senegal and Mali: Prior to stopping treatment in the three foci (Gambia, Faleme and Bakoye) results of an epidemiological and entomological evaluation showed prevalence and transmission levels near zero after 18-19 years of treatment. Based on this scientific evidence, treatment was stopped in core cluster of the village. The JAF was informed that a recent evaluation showed that there had been no infection and transmission after a year and a half to two years of no treatment. a) Guinea Bissau: The OCP, funded by the Gates Foundation begun elimination efforts in Rio Geba focus in 1996, after six years of treatment. Surveys in 2007 conducted 12 years after the last treatment showed that there had been no infection and transmission in the focus. b) Nigeria: A recent epidemiological and entomological evaluation showed zero prevalence in Kaduna focus after 16-19 years of treatment. The second phase of the study to be conducted in 2009, will involve stopping treatment in a test area, after which preliminary conclusions will be drawn before stopping treatment throughout the focus 43. The research team informed JAF that a key priority for 2009 was to determine to what extent these findings could be extrapolated to other countries or areas. The feasibility and timeframe of elimination was predicted to vary with treatment coverage both within the focus and neighbouring foci and would very much depend on the pre-control endemicity level. 44. The JAF commended this historic development, stressed the importance of continued surveillance in these onchocerciasis free foci, and looked forward to the results of similar studies to be carried out in other APOC countries in 2009. JAF15.4 Page I I 45. Given the shift in the programme that is underway towards a focus from control to elimination, based on emerging scientific evidence, there is the need to establish a working definition of the word 'elimination'. APOC management informed the JAF that the issue would be discussed at an elimination meeting to be held in February 2009, the outcome of which would be shared with ministers, donors and JAF members. Following the experiences in Uganda, the National Onchocerciasis Task Forces of countries were urged to develop similar elimination strategies. Recommendations of the Uganda Onchocerciasis Elimination (UOEC) 46. The UOEC is a Uganda Programme for Elimination of Onchocerciasis (UPEO) advisory body composed of national and international experts, which conducts annual review, monitoring and evaluation of UPEO activities and recommends effective approaches and methods for hastening onchocerciasis elimination. Its strategy is threefold; twice-yearly treatment with ivermectin using community-directed treatment approach, vector elimination where feasible, and targeted vector control where needed in order to put pressure on the vector. At its first meeting held in Kampala I l- 12 August 2008, the UOEC's key recommendations focused on the infectivity of flies, nodulectomy and national capacity building/training. The Committee also noted that onchodermatitis should not be used as an indicator in impact assessment since skin manifestations become nonspecific as infection rates decrease. Report of the final evaluation of the (SIZ) of the former OCP countries 47. Five countries were evaluated: Benin, Guinea and Togo, where geographical and therapeutic coverage targets were met and Ghana and Sierra Leone where encouraging trends were observed. The overall conclusion was that 85o% coverage is achievable and can be sustained. Among the challenges observed was the issue of census registers which was complicated by new community identification and migrant populations. Secondly, the number of female CDDs was generally low and this issue needed to be addressed within the cultural context and not from a pre-conceived norm about gender balance. 48. While some CDDs continued to agitate for incentives, there were some good examples of community-driven reward system in place, in some areas. The evaluation team noted that it could be useful to document and share best practices from good performing communities with an incentive system for their CDDs. The conhibution of the NGDOs (both financial and otherwise) in supporting sustainability throughout SZ was acknowledged and SIZ countries were encouraged to intensiff efforts to mobilise additional funding from various sources. The evaluation team concluded that SV objectives had been broadly achieved but challenges remained, including the fact that onchocerciasis control activities remain largely dependent on external funding sources, in spite of the commitment of governments. 49. Following the presentation, key observations were made: a) The JAF noted that in order to build on the success of the SZ, and to sustain surveillance activities, there was a need to build human capacity at the country level, especially by the recruiting and training of entomologists, epidemiologists and laboratory technicians. APOC and former OCP countries were encouraged to work toward achieving therapeutic coverage of at least 80% instead of the current 650%. b) To address the re-occurring issue of incentives for CDTI volunteers, the JAF recommended the development of a policy on incentive at country levels, in order to motivate volunteers and eliminate the risk of negative competition among programmes. JAFI5.4 Page 12 c) The JAF urged APOC management to recruit gender experts to address the challenge of gender mainstreaming in the programme's operations, while seeking the assistance of the African Development Bank and Canada. The assistance will enable the programme to develop country-specific strategies to increase women participation in CDTI activities, taking into account cultural and social norms. APOC reiterated its commitment to gender issues and informed JAF that the annual scholarship from the Trust Fund, for capacity building would be allocated on a male/ female ratio of l:2. Research on MACROFIL 50. In 2008, the transdermal delivery technology-based Diethylcarbamazine (DEC) patch was tested in the studies in Senegal and Mali on the feasibility of stopping ivermectin treatment. The results suggest that the patch has the characteristics required for use in surveillance of residual or resurging onchocerciasis. Upon a positive outcome of the ongoing TCC review of the technical, clinical and field study data, national health authorities will be asked for authorization of large scale surveillance use of this patch. 51 . The cornerstone of the strategy for development of tools for detection of potentially emerging ivermectin resistance are the ivermectin efficacy surveillance sites which will be set up by APOC. Skin snips will be obtained at these sites before CDTI and 3 months post-CDTI. The microfilaria genome will be analysed and the data assessed for correlation with response to ivermectin. The TCC recommended that 3 African Centres be set up for sample storage, genetic analysis and data analysis. The centres should be financially supported by the respective countries and work as a network and with the MDSC as a continental reference centre and in collaboration with centres in the developed countries for capacity building and technology transfer. While onchocerciasis would be the initial priority of the centres, they would expand to other diseases. 52. The proof-of-concept study on the safety and effect of two-monthly doses of 800 mg albendazole on Loa loa was completed in Cameroon. 60 subjects with >15000 mf/ml Loa loa microfilaria were included in the study. Data analysis is ongoing. The final data will be assessed to determine whether the effect of at least one of the albendazole regimens on Loa loamicrofilaremia was sufficient to justiff further research on albendazole for Loiasis and on the type of research to be conducted to support advances in ivermectin treatment in Loa loa co-endemic areas. 53. The Proof-of-concept study on the pharmacokinetics, safety and efficacy of moxidectin, developed for its potential as a macrofilaricide, in around 170 subjects infected with O. volvulus ln Ghana completed enrolment and initial follow up. Based on the fact that preliminary analysis of the blinded data suggests that microfilaricidal efficacy and associated safety of moxidectin are comparable to that of ivermectin, the Phase 3 study in around 1500 subjects will be initiated in Liberia, DRC and Ghana in the first quarter of 2009. Infrastructure preparation (construction or renovation of Clinical Research Centres, provision of all necessary equipment and consumables), personnel capacity building and review of submissions for necessary approvals by country authorities are completed in Liberia and ongoing in DRC and Ghana. Around US$ 6 million needs to be raised for completion of the Phase 3 study as well as the paediatric study and the community studies. Health Impact Assessment of APOC operations 54. Findings of the assessment impact of APOC operations, a collaborative venture between the Erasmus University, the Netherlands and APOC were presented. The presentation updated HIA estimates on capacity building and operational research, as they relate to onchocerciasis morbidity reduction (eye and skin disease, itching). Based on simulate trends in prevalence of infection and disease until20l5, using ONCHOSIM, the number of prevented disease cases in APOC countries in 2008 were: lnfection: 25,719,000,Itch: 4,186,000, Low vision 746,000 and Blindness 265,000. APOC achieved a further increase in Disability Adjusted Life Years ( DALYs) saved in the last two JAF15.4 Page 13 years and the projection is to save 1.5 DALYs by 2015, compared to about one million in 2008 and more than 500,000 in 2006. 55. Following the presentation, the JAF made the following observations a) The JAF was pleased with the report of the Health Impact Assessment (HIA) of APOC, which illustrated the benefits of the programme's activities to the health systems and the poor rural communities. The forum pointed out the need to complement these achievements with an assessment of the programme's socio-economic impact. b) The JAF stressed the importance of geographical coverage data and the need for training and capacity building for HI-A to start in earnest. Epidemiological and entomological studies are required for better knowledge of health impact, and for decision support regarding stopping of ivermectin treatment and surveillance. c) The research team was encouraged to publish the data to serve as an effective tool for advocacy and fund raising activities. Audit Report 56. The Forum took cognizance of the Auditor's report, through its reading by a representative of the Legal Counsel of WHO, and accepted it. Addendum to the Plan of Action and Budget 2008-2015 57. The JAF commended APOC management for a well prepared Addendum to the PAB 2008- 2015. The Addendum containing a financial commitment of US$ 36, 431, 160 was approved. However, JAF considered that this was a conservative figure given the expanded mandate of the programme and that an additional budget would be required to meet the objectives detailed in the addendum. The JAF requested APOC to present to the CSA a supplementary Addendum containing the necessaryjustifications for that purpose, for final approval by JAFl5. Plan of Action and Budget for 2009 58. The JAF approved the Plan of Action and Budget for 2009 and the corresponding budget in the amount of US$ 20,490,000. 59. Based on the request by JAF, APOC agreed to present to future JAF sessions a more detailed activity and country-specific breakdown of the programme's annual budget. Financing APOC 60. The total budget for APOC projected by the World Bank in its presentation was about US$ 114 million for the period 2008-2015. The Bank informed the JAF of a funding gap of about US$ 20, 000, 000 and recognizing the importance of APOC activities in strengthening health systems and efficient drug delivery, called on the donors to fillthe funding gap. Donor Pledges 61. Despite the global financial crisis, the international donor community reaffirmed their commitment to onchocerciasis control in Africa, with these additional pledges: JAF15.4 Page 14 a) African Development Bank: From the US$ 23 million pledged during JAFI3 for the period 2008-2015, the first disbursement of US$ 4 million will be made in 2008. b) Belgium: € I . 6 million, for the period of 2008-20 I 5 c) Canada: Will continue to support APOC for as long as necessary and is expected to make a financialpledge by March 2009. d) DFID: Signed a notice of contribution to the APOC Trust Fund for f,500,000 for 2009. e) France: Will continue their support mainly through NGOs. 0 Juhel Nigeria Drug Firm: Pledged to produce generic praziquantel for donation and sale. g) The Kuwait Fund: US$ 1.5 million for the phasing out stage. Kuwait also extended an invitation to African ministers of health for partnerships talk for the strengthening of health infrastructure. h) Merck & Co Inc., From the US $25 million pledged in2007, agreed to release US$ 3.1 million in 2009. i) The Netherlands: US$ 6 million for the period 2008-2009 j) The NGDO's Group: The NGDO Group as implementing partners, reiterated their continued commitment to the programme and the same level of financial support as in 2007. k) Kingdom of Saudi Arabia: US$ 2 million annually till 2015. The Kingdom of Saudi Arabia also extended an invitation to African ministers of health for partnership talks for the strengthening of health infrastructure. l) World Bank: US$ 2 million annually till2015 m) USAID: Recently pledged US$ 2 million to APOC for co-implementation initiatives of NTDs inTanzania and DRC, which will begin in2009. The Agency also pledged to work with other donors to bridge the funding gaps, drawing from the US$ 350 million presidential initiatives. 62. APOC management on behalf of the beneficiary communities expressed their profound appreciation for the donations and reassured the donor countries and institutions, of the programme's commitment to the elimination of onchocerciasis in Africa. Activities in ex-OCP countries 63. The 2007 epidemiological surveys conducted in Burkina Faso (13 villages), Mali (60) and Senegal (28) indicated that prevalence in all the villages was lower than the 5% threshold, except Burkina Faso, in the Comod/L6raba basin, where 1 village had prevalence of 17,32%0 and CMFL of 0,56. ln Cote d'Ivoire (44 villages) and Guinea Bissau (33), indicated that prevalence was lower than the 5%o threshold in all villages, except 4 villages in Cote d'lvoire with prevalence ranging from 5.81% to 39.3%o and CMFL of 0,52-2.72. An epidemiological survey conducted in Guinea Bissau in 2008, indicated that prevalence was lower than the 5%o in the 27 villages evaluated. ln Benin, 16 villages were evaluated, 14 showed prevalence of below 5%o, and2 above 5%. All the CMFL were <0,5. JAFI5.4 Page 15 64. Five years after the closure of OCP, entomological-epidemiological parameters in most of the ex-OCP countries have been maintained below the acceptable levels: prevalence <5%, CMFL <0.5 and infectivity rate <0.5yo. However,. in order to consolidate the gains and prevent risk of recrudescence, countries must continue CDTI activities and conduct adequate surveillance, particularly those that had to intemrpt treatment for years, due to sociaUpolitical unrest (C6te d'Ivoire, Guinea Bissau) and those where entomological-epidemiological results are not satisfactory (Ghana, lower M6 in Togo and Kolente in Guinea) 65. The JAF commended former OCP countries for their efforts and urged them and parhrers to safeguard the gains of OCP. Activities of the Multi-Disease Surreillance Centre (MDSC) 66. The main objective of the MDSC is to support enhanced lntegrated Disease Surveillance (IDSR) in the 1 I OCP countries in order to safeguard the gains of 28 years of onchocerciasis control. The results of onchocerciasis surveillance activities in 2008 were presented: technical support had been given to 9 ex-OCP countries for the analysis of vector populations and parasites, feedback had been given to seven out of these nine countries carrying out surveillance or research activities on the level of disease transmission and lastly, an epidemiologist consultant has been recruited by the MDSC to strengthen onchocerciasis surveillance. 67. The JAF was also informed that the process of granting autonomy to MDSC by the WHO was well in advance and once completed, the Centre will set up a governing body and be open to co- sponsors and partners. The name of the Centre will also change to the Ouagadougou Centre of Disease Control, O-CDC. 68. The key role played by the MDSC in onchocerciasis surveillance was appreciated and more support was requested from countries and partners to strengthen disease surveillance activities in Africa. Other matters 69. The West African Health Organization (WAHO), which currently attends the JAF as an observer expressed a wish to become a member of the JAF. This request was duly noted by the secretariat, which will submit the request to the CSA for consideration. 70. The JAF thanked Dr Ousmane Bangoura, who retired from the World Bank, for his long- standing contributions to onchocerciasis control in Africa. 71. The Equatorial-Guinea delegation made a request for Spanish interpretation of JAF proceedings. This request was duly noted by the secretariat, which will submit the request to the CSA for consideration. Date and place of JAF1S 72. At the kind invitation of the African Development Bank (AfDB), the 15th Session of the JAF will be held in Tunis, Tunisia. The dates will be communicated to JAF members in the coming months. Review of Final Communiqu6 73. The Final Communiqu6 was reviewed and adopted. JAFI5.4 Page 16 Closure of the fourteenth JAF Session 74. [n her closing remarks, the APOC Director, on behalf of the management and staff, expressed her profound gratitude to the Government and people of Uganda for the warm hospitality extended to JAF members during the meeting. She thanked the donor community and all APOC partners for their unflinching support and new pledges and reassured them that their unwavering support and investments would motivate APOC and disease control managers in countries to do more for poor, hard-to-reach commun ities. 75. The chairman thanked JAI for selecting Uganda to host JAF14, and commended participants for the intensive and quality deliberations. He also thanked donors, development partners and all stakeholders for their collective resolve and efforts to rid the world of onchocerciasis. The chair noted that JAFI4 had offered Afiica an opportunity to advocate not only for onchocerciasis control, but also the control of NTDs. He commended APOC for supporting the National Organizing Committee to ensure a successful meeting and thanked Dr Amazigo in particularly, for ably steering the APOC secretariat and for the tremendous achievements of the programme. Annexes JOINT ACTION FORUM Office of the Chairman JOINT ACTION FORUM Fourteenth session Kampala. Uganda. 8-11 December 2008 Annex I African Programme for Onchocerciasis Control (APOC) Programme africain de lutte contre I'onchocercose JAF-FAC JAF15.4 Page 17 FORUM D'ACTION COMMI.INE Bureau du Pr6sident ORIGINAL: ENGLISH December 2008 02. 03. LIST OF PARTICIPANTS/LISTE DES PARTICIPANTS APOC COUNTRIES/PAYS APOC Burundi 0t Dr Norbert BIRINTANYA, Coordonnateur National Onchocercose, Programme National de Lutte contre l'Onchocercose (PNLO), B.P. 1820, Bujumbura, Burundi - Tel : (257) 22 24 93 34 - Fax : (257) 22 24 91 96 - E-mail : birintanya@yahoo.fr Cameroon/Cameroun Monsieur Andr6 MAMA FOUDA, Ministre de la Sant6 Publique, Yaound6, Cameroun - Tel (237 ) 22 220-17 2 - Fax : (237) 22 220 -233 - E-mail : andrmama@yahoo.fr Professeur Gervais ONDOBO ANDZE, Directeur de la Lutte contre la Maladie, Directeur de la MALA/Pr6sident du GTNO, Ministdre de la Sant6 Publique, Yaound6, Cameroun - Tel : (237) 22239-348 (237) 99 86 44 0l Fax: (237) 22224-419 E-mail : and ze gervai s@yahoo. fr 04. Dr Marcelline NTEP, Coordinateur du Programme National de lutte contre l'Onchocercose/ Secr6taire Ex6cutif du GTNO, Ministdre de la Sant6 Publique, Yaound6, Cameroun - TeVfax: (237) 22226-910 - Cellulaire: (237) 99 81 08 01 I (237) 77 30 0l 60 - E-mail: sgoa@camnet.cm; mangamar200 I @yahoo.fr Chad/Tchad Dr Salim Hassane SALIM, Repr6sentant du Ministre de la Sant6 Publique, BP 440, N'Djamena, Tchad - Tel: (00235) 6 291 637 - Fax: (00235) 2 516 289 - E-mail: salimaphary@yahoo.fr Dr Ndeikoundam NGANGRO MOSUREL, Directeur des Activit6s Sanitaires, Ministdre de la Sant6 Publique, BP 440 N'Djamena, Tchad - Tel : (00235) 2 52 28 66 - E-mail : ndeikoumdam@yahoo.fr 05 06 JAF15.4 Page 18 07 Dr Lokemla NADJILAR, Coordonnateur du Programme National de Lutte I'Onchocercose, Ministdre de la Sant6 Publique, BP 440 N'Djamena, Tchad - Tel : 235 2 524 838 1235 6290164 - (00235) 2 524 838 - E-mail : nadjilar@yahoo.fr contre (00235) Republic of the Congo/R6publique du Congo 08. Dr Frangois MISSAMOU, M6decin-Chef du Programme National de Lutte contre l'Onchocercose (PNLO), Direction de la Lutte contre la Maladie, Ministdre de la Sant6 Publique, BP 1066, Brazzaville, R6publique du Congo - Tel : (242) 525 49 4l - (242) 668 0563 - E-mail : opc_congo@yahoo.fr Democratic Republic of the Coneo/&ipublique ddmocratique du Conso 09. Mr. Juvenal YAV, Head of Delegation, Embassy of Democratic Republic, Kololo phRoad# 22, Kampala, Uganda - Tel : +256 (0) 7 55057525 - E-mail : vaviuvenal3@vahoo.fr 10 Dr Marcel NUKENGESHAYI KUPA, Coordonnateur National, Programme National de lutte contre I'Onchocercose, 36, Avenue de la Justice, Commune de la Gomb6, BP 8081, Kinshasa I, R6publique D6mocratique du Congo - Tel : (2430 9999 47 13819979 71 365 - Fax : (243) 12 33 247 -E-mail : mukkupa@yahoo / polno_rdc@yahoo.fr Ethiopia/Ethiopie 11. Mr. Gole Ejeta YEMBO, Vector Biology Expeft, Ministry of Health of Ethiopia, P.O. Box 1234, Addis Ababa, Ethiopia - Tel: +251-ll5-503-835 - Fax: +251-115-534-867 - E-mail: gole_ejeta@yahoo.com Eq uatorial Guinea/Guinde Equatoriale 12. Mme Maria De La Vida ASUE NDONG, Vice Ministre de la Sant6, Ministdre de la Sant6 et du Bien-Etre Social, Malabo, Guin6e Equatoriale - Tel : (240) 256865 13. Dr Anacleto SIMA NSUE, Directeur National, Programme Oncho/Filariasis,, Ministdre de la Sant6 et du Bien-Etre Social, Malabo, Guinde Equatoriale - Tel : (240)232620 Liberia 14. Dr Walter T. GWENIGALE, MD, Minister of Health, Ministry of Health & Social Welfare, Capitol Bye-pass, P.O. Box 10-9009, Monrovia 10, Liberia - Tel: +231652 3669 - E-mail: wtgiveni gale@uuplus. com l5 Dr Bernice T. DAHN, MD, Deputy Minister for Health Services & Chief Medical Officer, Ministry of Health & Social Welfare, Capitol Bye-pass, Monrovia, Liberia - Tel: +231 655 7 636 - E-mail: bernicedahn59@yahoo.com Malawi 16. Mrs. Veronica NKUKUMILA, SEHO (DOC0), Chikwawa District Health Office, P.O. Box 32, Chikwawa, Malawi Tel: +265 1420 266 Fax: +2651420 264 - E-mail: veron icankukumila@yahoo.com 17. Mr. Laston SITIMA, National Coordinator, CHSU, PlBag 65, Lilongwe, Malawi - Tel: +265 | 750 896 I + 265 I303 446 - Fax: +265 I 753 308 - E-mail: lastonsitima@yahoo.co.uk JAF15.4 Page 19 18. Mr. C. KANGOMBE, Secretary for Health, Ministry of Health, P.O. Box 30377, Lilongwe 3, Malawi -Tel: +265 1789 403 -Fax: +265 1788 403 - Cell: +265 9 938 555 -E-mail: p health@africa-onl ine.net 19. Mr. Maxwell SIMKOZA, Assistant Human Resource Management Officer, Minister of Health, Box 30377. Lilongwe 3, Malawi - Tel: +265 8397 254 I +265 1789 400 - E-mail: maxwell oo.com Nigeria 20. Dr Anthonia Ngozi, NJEPUOME, Consultant Special Grade I, Department of Public Health, Federal Ministry of Health, Abuja, Nigeria Tel: +234 8056010207 E-mail: nogonjep@yahoo.com 2t Mrs Patricia OGBU PEARCE, Ag. National Coordinator, National Onchocerciasis Control Programme (NOCP), Federal Ministry of Health, Federal Secretariat, Phase III, Shehu Shagari Way, P.O. Box 083, Garki - Maitama, Abuja, Nigeria -Tel: +234-8035613104 Email :peie2 ahoo.com Sudan/Soudan - South Sudan/Sud Soudan 22. Dr Tabita SHOKAI, Federal Minister of Health, Ph.D. Nursing Research Masters of Nursing, B.S.C. Nursing Diploma in Nursing GN - Diploma Counseling, Khaftoum, Sudan - Tel: +00249 9 123 091609 - Fax: + 00249 183 774381- E-mail: tabita-shokai@fmoh.eov.sd 23. Dr Chor Malek TONG, National Coordinator, National Onchocerciasis Control Programme (NOCP), Federal Ministry of Health, Prevention of Blindness Administration, Nile Avenue, P.O. Box 631 Khartoum, Sudan - Tel: +249 183 741422 - Fax: +249 183 741421- Mobile: +249913039481 - E-mail: tong_schewitaak@yahoo.co.uk - tong_schewitaak@hotmail.com sudanoncho@hotmai l.com 24. Dr Mohamed FIANAN, Researcher, Department of Parasitology, P.O. Box 287, Federal Ministry of Health, National Onchocerciasis Control Programme (NOCPO, Khartoum IIII, Sudan -7s11 +249 9 2457392 - Fax: +249 183741421 - E-mail: hanan.mohamed@email.com 25. Dr Jan KOLACZINSKI, Neglected Tropical Diseases Specialist, Malaria Consortium Africa, Plot 2, Sturrok Road, P.O. Box 8045, Kampala, Uganda - Tel: +256 (0) 312 300 420 I + 256 (0) 752744 048 - Fax: + 256 (0) 312300 425 -E-mail: i.kolaczinski@malariaconsortium.org 26. Dr John RUMLINU, Director General, Preventive Medicine, Ministry of Health, Government of Southern Sudan, Public Health SpecialisVGeneral Medical Practitioner -Tel: +256 477108417 - E-mail: j rumunu@yahoo.com Tanzania/Tanzanie 27. Prof David H. MWAKYUSA (MP), Minister for Health and Social Welfare, P.O. Box 9083, Samora Avenue, Dar-es-Salaam,Tanzania-Tel: +255 222127192 - Fax: +255 22 2138060 - Email: dmwakyusa@moh. go.tz 28. Mr. Titus Aloyce MKAPA, Personal Assistant to the Minister of Health, Ministry of Health and Social Welfare, P.O. box 9083, Samora Avenue, Dar-es-Salaam, Tanzania - Tel: +255 22 217192 - Fax: +255 22 21380060 - E-mail: tamkapa@yahoo.com JAFI5.4 Page 20 29. Dr Peter MMBUJI, Assistant Director, Preventive Health Services, Ministry of Health and Social Welfare, P.O. Box 9083, Samora Avenue, Dar-es-Salaam, Tanzania - Telffax: +25522 2 13 6803 - E-mail : mmbu i i@vahoo.co.uk 30. Mr. Oscar Christian KAITABA, Ag. Programmed Manager, National Eye Care & Onchocerciasis Control Programs (NOCPA{ECP), Ministry of Health and Social Welfare, P.O. Box 9083, Samora Avenue, Dar-es-Salaam, Tanzania - Tel/Fax: +255 22 2l30OO9 - Mobile: +255 754 889390 - E-mail : ockaitaba@yahoo.com Uganda/Ouganda 3 1. Dr Stephen MALINGA, Hon. Minister of Health, Ministry of Health, P.O. Box 7272,Kampala, Uganda - Tel: (256) 414340-8711414 340-874 - Fax: (256) 414231-584 - E-mail: smal inga@health. go.ug 32 Dr Richard NDUHURA, Minister of State for Duties, Ministry of Health. P.O. Box 7272, Kampala, Uganda - Tel: - Fax: - E-mail: 33 Dr Emmanuel OTAALA OTIAM, Minister of State For Health, (Primary Health Care), Ministry of Health, P.o. Box 7272. Kampala, Uganda - Tel: + 256 772 430 720 - Fax: +256 414 253 802 - E-mail: emmotaala@yahoo.corn 34 Dr Sam ZARAMBA, Director General of Health Services, Ministry of Health, P.O. 7272, Kampala, Uganda Tel: +256 414 340873 Fax: +256 414 340881 E-mail: zarambasam o.co.uk 35 Dr D.K.W. LWAMAFA, Commissioner of Health Services, Department of National Disease Control, Ministry of Health, P.o. Box 7272,Nakasero, Kampala, Uganda - Tel: (256) 414 259- 666 -Fax: (256) 414 231-5721414 231-584 - E-mail: lwamafa@yaho.co.uk 36. Dr John Bosco RWAKIMARI, Coordinator, National Onchocerciasis Control Programme(NOCP), Ministry of Health, P.O. Box 7272,Kampala, Uganda Tel: (256) 414-348-332 - Fax: (256) 414 -34-339 - Mobile: (256) 712-042-129 - E-mail: dr_jbr@,vahoo.com 37. Dr Richard NDYOMUGYENYI, Manager, Malaria Programme, Ministry of Health, P.O. Box 7272,Kampala, Uganda - Tel: (256) 772 457-980 - E-mail: richardndyomuygenyi@yahoo.com OCP COUNTRIES/PAYS OCP B6nin 38 Dr Moussa YAROU, Directeur de Cabinet au Ministdre de la Santd Publique, B.P. 882, Cotonou, Rdpublique du B6nin - Tel : + 229 33 65 78 - Fax : +229 33 04 64 - E-mail: varoum02@yahoo.fr 39 Dr Paul Franck Roland SINTONDJI, Coordonnateur National Adjoint du Programme National de Lutte contre l'Onchocercose (PNLO), PNLMT/DNPSA4S, 0l B.P. 882, Cotonou, R6publique du Bdnin - Tel/Fax : +229 21 33 87 l7 - E-mail : sentofranck@yahoo.fr Burkina Faso Dr Sylvestre Roger Marie TIENDREBEOGO, Directeur de la Lutte contre la Maladie, Ministdre de la Santd Publique, 07 BP 153 Ouagadougou 07, Burkina Faso - Tel : (00226) 50 33 49 38 - Fax : (0026) 50 31 54 40 - E-mail: syltien@hotmail.com 40 44 JAFI5.4 Page2l 4t M. Xavier PITROIPA, Responsable de la Cellule Entomologique, Ministdre de la Sant6 Publique, 07 BP 5153 Ouagadougou 07, Burkina Faso - Tel: (00226)70 42 08 37 - E-mail: leopitroipa@fasonet. bf Ghana 42. Dr Nana-Kwadwo BIRITWUM, Programmed Manager, Neglected Tropical Diseases Control Programme, Ghana Health Service, P.O. Box MB-190, Accra, Ghana - Tel: + 233-21-670-102 - Mail: +233-21-226-739 - E-mail: nan.biritwum@hru-ghs.org / nkadbiritwum@gmqil.com Republic of Guinea/Rdpublique de Guin6e 43 Son Excellence Docteur Mariame BEAVOGUI, Ministre de la Sant6 et de l'Hygidne Publique, Ministdre de la Santd et de l'Hygidne Publique, BP 585, Conakry, R6publique de Guinde - Tel : (+224) 60 23 31 61 I 64 26 07 50 - E-mail : beavoguimariame@yahoo.fr Dr Andr6 GOEPOGUI, Coordonnateur Adjoint du Programme National de lutte contre l'Onchocercose et la Cdcitd (PNLOC), Ministdre de la Santd et de l'Hygidne Publique, BP 585, Conakry, R6publique de Guinde - Tel : (+224) 60 29 31 59 - E-mail : agoep@yahoo.fr Togo 45 Dr K. Potochoziou KARABOU, Coordonnateur, Programme National de Lutte contre l'Onchocercose, BP 487 / DRS/ Kara, R6publique du Togo - Tel: (228) 660 12 l0 / 660 00 35 - Cellulaire : (228) 902 47 95 - Fax : (228) 660 04 14 - E-mail : karaboup@,yahoo.fr DONORS/DONATEURS African Deve lopment B ank/B anque Africaine de D6veloppement Dr Maimouna DIOP LY, Health Analyst, African Development Bank, 13 Avenue du Ghana, B.P. 323, 1002 Tunis Belvdddre, Tunisia - Tel: (216) 71.103.435, Fax : (216) 71.33.25.75 - E- mail: m.dioply@afdb.org 47 Ms. Yeshiareg DEJENE, Senior Gender Expert, Human Development Department (OSHD), African Development Bank, 13, Avenue du Ghana, BP 323, 1002 Tunis Belv6ddre, Tunisia - Tel: (216) 7ll0-3454 - Fax: (226) 71332575 -E-mail: y.dejene@.afdb.org 48 Mr. Benedict KANU, Officer in Charge, African Development Bank, P.O. Box 28509, ruh Floor, Crested Towers, Kampala, Uganda -Tel: +256 414 234 086 - E-mail: b.kanu@afdb.org Belgium/Belgique 49. Dr Daniel CEUNINCK, Conseiller, CD SPF Ministdre des Affaires Etrangdres, Rue des Petits Carmes 8-1000 Bruxelles, Belgique - Tel : 32 2 501 4918 - Fax: 32 2 501 4570 - E-mail : dani.ceuninck@d iplobel.fed.be Canada 50. Dr Pierre-Claver BIGIRIMANA, Health Specialist, Policy, Strategic, Planning and Technical Services, Africa Branch, CIDA, 200 Promenade du Portage, Gatineau (Qu6bec), Canada KlA 0G4 - Tel: (l-819) -953-2086 - E-mail: pierre_bigirimana@acdi-cida.gc.ca 46 JAFI5.4 Page22 France Dr Marc LEJARS, Regional Health Adviser (Kenya, Tanzania, Uganda, Burundi), Embassy of France in Kenya, Barclays' Plaza Tower, P.O. Box 41784 00100 Nairobi, Kenya Tel: +254 (20) 277 87 40 - E-mail : marc.leiars@di lomatie.gouv.fr Kuwait Fund for Arab Economic Development 52. Dr Abdul-Redha BAHMAN, Agricultural Advisor, Kuwait Fund for Arab Economic Development, P.O. Box292l, Safat 13030, Kuwait - Tel: +965 29 999 000 - Fax: +965 29 99 190/ 1 - E-mail: bahman@kuwait-fund.org 53. Dr Ibrahim AL-KULAIB, Researcher, Kuwait Fund for Arab Economic Development, P.O. Box 2921, Safat 13030, Kuwait - Tel: +965 29 999 000 - Fax: +965 29 99 lg0l1 - E-mail: ibrahim@ku wait-fund.org Merck and Co. Inc. 54 Mr. Kenneth M. Gustavsen, Director, Global Health Partnerships, Merck & Co., Inc. WS 2A 56, One Merck Drive, P.O. Box 100, Whitehouse Station NJ 088889-0100, USA - Tel: (908) 423 3088 - Fax: (908) 735 1839 - E-rnail: ken qustavsen@marck.com The Netherlands/Les Pays Bas 55 Mr. A. H. Y. GALEMA, Deputy Head Health and Aids Division, Bezuidenhoutseweg 67,2500 EB, The Hague, The Netherlands - Tel: + 31 70 348 7434 - Fax: +31 70348 5366 - E-mail: anno. galema@minbuza.nl Saudi Arabi al Ar abie Saoudite 56. Eng. Hasan A. ALATTAS, Director General, Technical Department, P.O. Box 1887, The Saudi Fund for Development, Riyadh ll44l, Kingdom of Saudi Arabia - Tel: +9661 4641928 -Fax: +9661 464 7450 - E-mail : abamaan@yahoo.com 57 Mr. Saud A. AI-FANTOUKH, Director General, Control & Audit Department, The Saudi Fund for Development, P.O. Box 50483, Riyadh 1887 - Kingdom of Saudi Arabia -Tel:+966 464 0723 - Fax: +966 464 7450 - E-mail: salfantoukh@gmail.com The World Band/Banque Mondiale 58. Dr C. Ok PANNENBORG, Senior Health Advisor & Interim Coordinator for Onchocerciasis, Africa Region Human Development Department, The World Bank, l8l8 H Street NW, Washington DC 20433, USA Tel: 202.473-4415 - Fax: 202.473-500 - E-mail: Opannenborg@worldbank.org 59 Dr Ousmane BANGOURA, Consultant for Onchocerciasis, Africa Region Human Development Department, The World Bank, l818 H Street NW, Washington DC 20433, USA -Tel: 202.473- 4004 - Fax: 202.473-8216 - E-mail: Obangoura@worldbank.org Mr. Alireza AZIMIPOUR, The World Bank, l8l8 H Street NW, Washington DC 20433, USA - Tel: 202- 458-21 8l - Fax: 202-4738216 - E-mail: aazimpour@worldbank.or 60 62 JAF15.4 Page 23 United States of America (USA)/Etats Unis d'Am6rique 61. Ms. Angela WEAVE& Infectious Diseases Advisor, Diseases, USAID, GIVHIDN/ID 307-27, Third Floor, Ronald Reagan Building, 1300 Pennsylvania Avenue, Washington,DC 20523 - Tel: (202) 772-5603 - Fax: (202) 216-3702 -E-mail: aweaver@usaid.gov United (DFID) - Centre for Neslected Tropical - Liverpool School of TropiqdMedlatng Mrs Joan FAHY, Liverpool School of Tropical Medicine Pembroke Place, Liverpool, 5QA - Tel: 44 l5 17053145 - Fax: 44 (0) 1517090354 - E-mail: fahy@liv.ac.uk NGDO/ONGD Carter Center 63. Dr Moses Nayenda KATABARWA, Program Epidemiologist, The Carler Center, 2nd Floor Kirbo Building, 1149 Ponce de Leon Avenue, AtlantaGA 30306, USA-Tel:770-488-4511 17 - Fax: 770-488-4521 - E-mail: vzk5@cdc.gov and mkataba@emory.edu Dr Frank WALSH, Chairman, Committee Programmed, the Carter Center, Uganda Onchocerciasis Elimination,80 Arwdel Road Lytham St. Annes Lanchshire FY8 IBN, Great Britain - Tel: 0044 1253 137765 - E-mail: frank@walsh.me.uk Catholic Medical Mission Board (CMMB) 65. Dr Salvador Garcia de la TORRE, Senior Medical Advisor & Regional Coordinator, Africa, Centenary House, l" Floor, Wing A, P.O. Box 1381l-00800, Westlands, Nairobi, Kenya - Tel: +254-20-4450437 Fax: +254-20-4450440 E-mail: Salvador@maf.or.ke and s gacciadelatorre@cmmb. org CBM 66. Dr Irmela ERDMAN, Medical Advisor, Eye Department, Mengo Hospital, P.O. Box 7161, Kampala, Uganda -Tel: +256-772-471-949 - E-mail: i.erdmann@gmx.net International Trachoma Initiative (ITI) 67. Mr. Ibrahim JABR, President, lnternational Trachoma lnitiative (ITI), 441, Lexington Avenue, Suite 1101, New York, NY 10017, USA - Tel: +212 490-6460 - Fax: +212 490 6461 - E-mail: ijabr@trachoma.org Light for the World 68. Mr. Philippe NARVAL, Program Officer, Light for the World, Nieder Hofstr 26, ll20 Vienna, Austria - Tel: +43 1810 1300 - Fax: +43 1810130015 - E-mail: p.narval@light-for-the- world.org Mr. Wolfgang GINDORFER, Senior Consultant, P.O. Box 33887, Kampala, Uganda - +256- 7 7 3 -035 17 6 - E-mail: w. gindorfer@light-for-the-world-.org 64 69 JAF15.4 Page 24 Lions Clubs International Foundation (LCIF) 70. Mr. Phillip ALBANO, Manager, Sight Programs Department, 300W, 22"d Street, OAK Brook IL 60523.8842, USA - Tel: 630 571 5466 - E-mail: Phillip.Alban ionsclubs.org 71 Dr Adrian HOPKINS, Director, Mectizan Donation Program, 325 Swanton Way, Decatur, GA- 30030, usA Tel +1 404-371-1460 Fax: +1 404-371-1138 E-mail: ahopkins@taskforce.org 72. Dr Kisito OGOUSSAN, Associate Director (Onchocerciasis), Mectizan Donation Program, 325 Swanton Way, Decatur, GA- 30030, USA - Tel +l 404-371-1460 - Fax: +l 404-371-1138 - E- mail : kosussan@taskforce org MITOSATH 73. Mrs. Francisca O. OLAMIJU, Executive Director, Mission to Save the Helpless (MITOSATH). 605 Hospital Place, Opposite Green Valley Suites, GRA, P.O. Box 205, Jos - Plateau State, Nigeria, Tel: (234) 73 464 792 - Mobile (234) 8033318085 - E-mail: mitosath@hotmail.com or olamij ufo@m itosath.org Neelected Tropical Diseases (NTD) Control Pro$amlUSA 74. Dr Dieudonn6 SANKARA, Senior NTD Specialist, 701 13m Street, NW, Washington, DC 20005, United States of America - Tel: +1-202-'728-2078 - Fax: +1 202-974-7892 - E-mail: dsankara@rti.org / sankdieup@yahoo.com Organisation pour la Pr6vention de la Cdcit6 (OPC) 75. Dr Bernard PHILIPPON, Membre du Conseil d'Administration d'OPC, 17 Villa d'Alesia, 75014 Paris, France - TeVFax : (0033l) 40 44 94 04 - E-mail : abphilippon@vahoo.fr Sieht Savers International (SSD 76 Dr Elizabeth O. ELHASSAN, Regional Director, Sight Savers International (SSf, West Africa Regional Office, Western Sector c/o 58 Patrice Lumumba Road, P.O. Box KIA 18190 Airport Accra, Ghana - Tel: +233 21 774210 - E-mail: elizabethelhassa(@yahoo.co.uk Mr. Simon BUSH, Director African Alliances and Advocacy, Sight Savers International (SSD, 58 Patrice Lumumba Road - Airport (Accra - Ghana) - Tel: +231 21 774210 - Fax: +231 2l 7 80227 - E-mail: sbush@sightsavers.org Dr Johnson NGOROK, Deputy regional Director, Sight Savers lnternational, P.O. Box 34690 00100 GPO Nairobi, Kenya - Tel: +254 722 567 897 - Fax: +254020 609 623 - E-mail: j n gorok@si ghtsavers.or.ke Mr. Benjamin K. MALE, Country Representative, Sight Savers lnternational (SSD, 2nd Floor, East African Development Bank, Nile Avenue, P.O. Box21249, Kampala, Uganda - Tel: (256) 414 230-299 - Mobile: (256) 772 859-593 - E-mail: bmale@sightsavers.org 77 78 79 Mectizan@ Donation Pro gram 80 JAFI5.4 Page25 United Front Aeainst Riverblindness (UFAR) 8l Dr Daniel SHUNGU, Chairman & Executive Director, United Front Against Riverblindness (UFAR), 13 Carnation Place, Lawrenceville, New Jersey 08648, United States of America - Tel: 609-771-3674 - Cell: 609-9543398 - Fax: 609-530-1594 - E-mail: dlshungu@aol.com Dr Shasta JONES, Director, Center for Health Promotion, University of Pennsylvania, Center for Health and Communication Research, 3535 Market Street, Suite 520, Philadelphia PA 19104-3309, United States of America - Tel: USA - 001-215-573-9500 - Fax: 001-215-573- 9303 South Africa - +27-43-704-7201 - Fax: +27-43-704-7202 E-mail: sjones@asc.upenn.edu wHo/HQ/GENEVA-OMS/SIEGE/GENEVE M. Claude-Henri VIGNES, Office of the Legal Counsel, World Health Organization (WHO), 20 Avenue Appia, CH-lzll, Geneva 27, Switzerland - 1s1'+41 22759'2022 - Fax: +41 22 791-4158 - E-mail: chvisnes@bluewin.ch Mr. Xavier DANEY, Legal Officer, Office of the Legal Counsel, World Health Organization (WHO), 20 Avenue Appia, CH- l2l 1, Geneva 2J, Switzerland - Tel: +41 22 791-1871 - Fax: +41 22 791-4158 - E-mail: daneyx@-yrha-intt Dr Annette Christiane KUESEL, Scientist, TDR, World Health Organization, 20 Avenue Appia, 1211 Geneva27, Switzerland, Tel: 41 22 791 l54l - Fax: 41 22 791 4774 - E-mail: kuesela@rvhajlt Dr Tony UKETY , NGDO Group Responsible Officer, World Health Organization (WHO) , 20 Avenue Appia, 121 I Geneva 27, Switzerland - Tel: +41-22-791-1450 - Fax : +41-22-791- 4772 - E-mail: uket-vt@who.int WHOruGANDA _ OMS/OUGANDA Dr Joachim SAWEKA, WHO Representative, World Health Organization (WHO) Country Office, Corner Kinh.r/Shimoni Road, P.O. Box 24578, Kampala, Uganda - Tel: +256 414 335500 - Fax: +256 414 335569 - E-mail: 87 Dr Myriam NANIYIJNJA, Disease Prevention and Control OfFrcer (DPC), World Health Organization (WHO) Country Office, Corner Kintu/Shimoni Road, P.O. Box 24578, Kampala, Uganda Tel: +256 414 335500 Fax: +256 414 335569 E-mail: nanyunj am@u g. afro.who. int 88 Dr Juliet BATARINGAYA, NPO/Health Systems Development, World Health Organization (WHO) Country Office, Corner Kintu/Shimoni Road, P.O. Box 24578, Kampala, Uganda - Tel: +256 414 335500 - Fax: +256 414 335569 - E-mail: bataringayaj@ug.afro.who.int 89 Mr. Joseph KAruBI, World Health Organization (WHO) Country OfFtce, Corner Kinnr/Shimoni Road, P.O. Box 24578, Kampala, Uganda - Tel: +256 414 335500 -Fax: +256 414 335569 - Mobile: +256 (0) 774 404463 - E-mail: kajubij@ug.afro.who.int WIIO/AFRO/RE GIONAL OFFICE/BI]REAU RE GIONAL OMS/AFRO Dr Ngenda MWIKISA, World Health Organization (WHO/AFRO), BP 06,Brazzaville, Congo - Fax : +47 24139388 - E-mail : mwikisac@afro.who.int 82. 83. 84. 85. 86 90 92. JAFI5.4 Page 26 WHOIVIDSC-OMS/}IDSC 9l Prof. Mandy Kader KONDE, Director a.i. , Multi Diseases Surveillance Center (MDSC), Avenue Naba Zombr6 No 1473, 0l B.P. 549, Ouagadougou 01, Burkina Faso - Tel.: (226) 70 20 02 63 - Fax : (226) 50 34 28 75 - E-mail : kondek@oncho.afro.who.int Dr Laurent TOE, Head of Molecular Biology Laboratory, Multi Diseases Surveillance Center (MDS), 1473 Avenue Naba Zombr6,01 BP 549, Ouagadougou 01, Burkina Faso, Tel. (226) 50 34 29 53 - Fax: (226) 50 34 36 47 - Email: toel@oncho.afro.who.int WHO/SECRETARIAT-SECRETARIAT OMS Dr Uche Veronica AMAZIGO, Director, APOC, Avenue Naba Zombr6 No 1473, 01 P.O. Box 549, Ouagadougou 01, Burkina Faso - Tel: (226) 50 34 22l7 -Fax: (226) 50 34 48 00 - E- mail : amazigouv@oncho.afro.who.int Dr Laurent YAMEOGO, Coordinator, Director's Office, APOC, Avenue Naba Zombrd No 1473,01P.O. Box 549,Ouagadougou 01, Burkina Faso - Tel: (226) 50 34 41 04 -Fax: (226) 50 34 28 75 - E-mail: yameogol@oncho.afro.who.int Dr Mounkaila NOMA, Chiel Epidemiology and Vector Elimination Unit, APOC, Avenue Naba Zombr6 No 1473, 01 P.O. Box 549, Ouagadougou 01, Burkina Faso - Tel: (226) 50 34 29 53 - Fax: (226) 50 34 28 75 - E-mail: nomam@oncho.afro.who.int 96 Mr Honorat Gustave ZOURE, Responsible, Biostatistics and Mapping, APOC, Avenue Naba Zombrd No 1473, 0l P.O. Box. 549, Ouagadougou 01, Burkina Faso - Tel: (226) 50 34 29 59 - Fax: (226) 50 34 28 75 - E-mail: zoureh@oncho.afro.who.int 97 Mr. Koffi Benoit AGBLEWONU, Budget and Finance Officer, APOC, Avenue Naba Zombr6 N" 1473, 0l P.O. Box 549, Ouagadougou 01, Burkina Faso - Tel: (226) 50 34 29 53 - Fax: (226) 50 34 28 75 - E-mail: agblewonuk@oncho.afro.who.int 98. Mrs. Patricia MENSAH, Senior Administrative Assistant, Sustainable Drug Distribution Unit, APOC, 0l P.O. Box 549, Ouagadougou 01, Burkina Faso - Tel: (226) 50 34 29 53 - Fax: (226) 50 34 28 75 - E-mail: mensahp@oncho.afro.who.int 99 Mrs. Marie-Emilie ZOUGMORE, Executive Secretary, APOC, Avenue Naba Zombrd No 1473, 0l P.O.Box549,Ouagadougou 0l,BurkinaFaso-Tel:(226)503429 60-Fax: (226)5034 28 75 - E-mail: zougmorem@oncho.afro.who.int ERASMUS MC T]NIVERSITY 100. Prof. J.D.F. HABBEMA, Professor of Medical Decision Sciences, Erasmus MC, Department of Public Health, P.O. Box 2040 3000 CA, Rotterdam, The Netherlands Tel:+31 l0 7038460 - E-mail: j.d.f.habbema@erasmusmc.nl APOC TECHNICAL CONSULTATIVE COMMITTEE 101 . Prof. Adenike ABIOSE, P.O. Box 2977 I , Secretariat Main Office, Ibadan, Oyo State, Nigeria Tel: 234-2 -7517329; 234-8037865702 - Fax: l-509-5628212 - E-mail: abiose@skannet.com or adenikeabioseo@yahoo.com 93 94 95 JAFI5.4 Page27 INTERPRETERS/TNTERPRETE S 102. Mr. Christian STENERSEN, 123 Les Rossanets, F-01170 Segny (France)-Tel : (33a) 50al 7880 103. Ms Genevidve CLEMENT, Le Parc du Jura, 42 avenue du Jura, F-01210 Ferney-Voltaire, France - Tel : 33 456820578 - E-mail : g.clement@club-internet.fr 104. Mme Safi6tou BARRY, 09 B.P. 526 Ouagadougou 09, Burkina Faso - Tel: (226) 50 46 02 82, Cellulaire (226) 70 21 41 14, E-mail : barrysafietou@yahoo.fr 105. Mr. Victor IMBOUA-NIAA, 3 Maple Crescent, DTD, Silver Bells 2, Regimanuel Estates, East Airport, Accra - Tel: (233) 21811934 - E-mail: vimbouaniava@yahoo.com 106. Professeur Michel KABORE (Traducteur) 01 B.P. 1444,Ouagadougou 01, Burkina Faso, Tel (226) 50 36 l3 83 - Cellulaire: (226) 70 27 05 96 RAPPORTEUR 107. Mr. Paul EJIME, WHO/APOC Communication Officer, Avenue Naba Zombr6 N" 1473, 0l BP 549 Ouagadougou 01, Burkina Faso - Tel: (00226) '1508484 I 70945194 - E-mail: ej imep@oncho. afro. who. int / pau l.ej ime@ gmai l. com 108. Ms. Elizabeth IryAMAYARO, Flat 3 Benbigh Street London SW1V 2EU United Kingdom - Tel: +0044 75315958 - E-mail: enyamayaro@hotmail.com OB SERVERS/OBSERVATEURS DANIDA/Danish Bilharziasis Laboratory (DBL) 109. Dr Erling M. PEDERSEN, Senior Scientist, DBL - Centre for Health Research and Development, Faculty of Life Sciences, University of Copenhagen, Thorvaldsensvej 57, l87l Frederiksberg C, Denmark - Tel: +45 35 33 1406 - Fax: +45 3533 1433 - E-mail: emp@life.ku.dk West African Health Oreanisation (WAHO) I10. Dr Johnson Jeanetta, Deputy Director General, West African Health Organisation (WAHO), 01 BP 153, Bobo-Dioulasso, Burkina Faso, Tel: (226) 75557955 - E-mail: jkoyah@yahoo.com and wahooas@fasonet.bf Wyeth Pharmaceuticals 111. Mr. Nand Kumar, Director Access, 500 Arcola Road Collegeville PA 19426, Philadelphia, United States of America - Tel : 484-865-3351 - Fax : 484-865-6419 - E-mail : kumarn@wveth.com JAF15.4 Page 28 NI-VITED GTIEST/ II{YITE ll2. Dr Catherine HODGKN, Director Development Policy & Practise, Royal Tropical lnstitute, P. O. Box 95001, l0 90 HA Amsterdam, The Netherlands - Tel: +31 20 5688 349 - Fax: +31 20 5688 444 - e-mail: c.hodekin@.kit.nl l13. DrHansF.REMME, l20ruedesCampanules 0120Ornex,France-Tel:+33 645457404- E-mail : hansremme@ gmail.com ll4. Dr Ifeanyi Okoye, C.E.O., ruFIEL Nigeria LTD, 35 Nkwubor Road, Emene, Enugu State, Nigeria - Tel : +00234 42 55 88 98 - Fax : +00234 42 55 88 99 - Mobile: +234 80-37391504 - E-mail : info@j uhelni geria.com 115. Prof. Rory POST, The National History Museum, Cromwell Road, London, United Kingdom - Tel: +44 (0)207-427-2087 -Fax: +44 (0)207-927-2918 - E-mail: r.post@nhm.ac.uk oBSERVERS (UGANDA)/OBSERVATEURS (OUGANDA) 116. Ms. Peace HABOMUGISHA, Country Representative, The Carter Center, Global 2000 River Blindness Program (G2000), P.O. Box 12027, Bombo Road Plot 15, Vector Control Division Building, Ministry of Health, Kampala, Uganda - Tel: (256) 414 251-0251414 345-183 - Fax: (256) 414 349-139 - E-mail: rvbprg@utonline.co.ug ll7. Mr. Jackson ABIGABA, Ministry of Foreign Affairs, Kampala, Uganda E-mail abijac@yahoo.com 118. Mrs. Hilda ABIO, LC5 Chairperson, Moyo district local Government P.O. Box 1, Moyo - Tel 0772 979 882 - Email: abiohilda@yahoo.com 119. Dr Francis ABWAIMO, District Health Officer, Box 904 Mbale, Uganda - Tel: +256 (0) 712 415 913 - E-mail: fabwaimo@yahoo.co.uk 120. Mr. William ACALE, District Health lnspector, Local Government, P.O. Box l, Koboko District, Uganda -Tel: +256 (0) 772 23ll9l1 - E-mail: agatawilliam@yahoo.com l2l. Ms. Stella AGLINYO, The Carter Center, Global 2000 River Blindness Program (G2000), P.O. Box 12027, Bombo Road Plot 15, Vector Control Division Building, Ministry of Health, Kampala, Uganda - Tel: (256) 414 345-1831414 251-025 - Mobile: (256) (0) 772 628 939 - E- mail : agunyoegunvu@yahoo.com 122. Mr. Ibrahim AIRIGA, RDC, Box l, Arua, Uganda - E-mail: +256 (0) 77071330 123. Mr. Patrick AGUMA, District Health lnspector (for D.H.O.), Environmental Health Science, Uganda - +256 (0) 772 668 995 124. Ms. Mariam AKANDRU, Koboko District Local Government, P.O. Box l, Koboko, Uganda - Tel: +256 (0) 772 573 262 I +256 (0) 755 573262 - E-mail: akandru-mariam@yahoo.com 125. Mr. Stephen Abwoye AKENA, Biostatistician, P.O. 1074, Gulu, Uganda - Tel: +256 (0) 773321 985 - E-mail: stevebwoye@yahoo.com JAF I5.4 Page29 126. Mr. Richard AMOLA, District Onchocerciasis coordinator, Environmental Health Offtcer, Adjumani District Local Government, Box 145, Adjumani, Uganda - Tel: +256 (0) 772 991 t9u+2s96 (0) 713 991 197 - E-mail: richardamola@yahoo.gqm 127. Mr. FeruaR. ANDAMA, LC5 chairman, P.O. Box l, Arua, Uganda-Tel: +256 (0) 755 515 577 or +256 (0) 772 575 577 -E-mail: aferuarichard@yahoo.com 128. Ms Martha ASIIMWE, Resident District Commissioner, Human Resource Manager, Hoima District -Tel:0772 988 888 I 0752 635 564 - Email: marthasiimwe@yahoo.com 129. Mr. Anthony Louis ATube-OMACH, Chairperson LC5, Amuru District Local Government, P.O. box 1074, Gulu, Uganda - Tel: +256 (0) 772 425 946 I +256 (0) 771 19l 681 - E-mail: aomach1955@yahoo.com 130. Mrs. Elizabeth AYUME, president District Commissioner, Koboko District Local Government, P.O. Box l, Koboko, Uganda -Tel +256 (0) 772 513 202 131. Mr. Charles BABIKLNryAMI, District Oncho Coordinator, Bushenyi Local Government, P.O. Box 1 Bushenyi 1, Uganda Tel: +256 (0) 772 604 112 E-mail: bab i kun-vam c har I e s@yahoo. c o m 132. Mr. Silver BAGMA, District Chairperson, P.O. Box 5, Kabale, Uganda - Tel: +256 (0) 772 584 2t5 133. Mr. Silver BAGUMA, District Chairperson, P.O. Box 5, Kabale, Uganda - Tel: +256 (0) 172 564 215 134. Dr Julius BALINDA, District Health Officer, Kjenjojo Disctrict Local Government, P.O. Box 1002, Kyenjojo, Uganda -Tel: +256 (0) 772 589 588 - E-mail: balindajulius@yahoo.com 135. Dr Julius BAMWINE, District Health Officer, Ibanda District, P.O. Box 388, Ibanda, Uganda - Tel: +256 (0) 752 338 417 - E-mail: jbamwins@-vahoo.co.uk 136. Mr. Edward BANOBA, District Onhocerciasis coordinator, Vector Control Officer, P.O. box 169, Kasese, Ugand - Tel:+256 (0) 772 595 3i4 - E-mail: ebanoba@yahoo.com I37. Mr Ntarweje Eruab BEGUIvIYA, Deputy CAO, Woncing in CAO's office, P.O. Box 38, Fort Portal,Kabarole - Tel: 0772 629 092 138. Mr. Ignatius BESISIRA, Resident District Commissioner, Kamwenge District, Uganda - Tel: +256 (0) 772 6s3 144 139. Mr. Edward BISANGABASAIJA, Administrative Officer, Box 2, Karunguza, Uganda - Tel +256 (0) 772 392 2l9l - E-mail: ebilangabasaija@yahoo.com 140. Dr Andrew BYAMTINGU, Deputy Coordinator, National Onchocerciasis Control Programme (NOCP), Vector Control Building, Ministry of Health, P.O. Box 7272,Kampala, Uganda - Tel: (256) 772 479-318 - E-mail: andybvamu@gmail.com l4l. Ms. Rita BIRUNGI, Secretary, President's Office, P.O. Box 7168 -Tel: +256 (0) 77 652017 - E-mail : ritabirun gi@yahoo.co.uk 142. Mr. Augustin Rukiika BUJARA, Ag. Chief Administrative Offrcer (CAO) Bududa, P.O. box 292,Bududa, Uganda - Tel: +256 (0) 772438631 - E-mail: rukiika@yahoo.co.uk JAFI5.4 Page 30 143. Mr. Frederick BYENUME, District Onchocerciasis Coordinator, Health Inspector, P.O. Box 2, Hoima, Uganda - Tel: +256 (0) 772 495 189 - E-mail: Byenume_frederickOT@yahoo.com 144. Mrs. Margaret CHOTA, Commissioner Health Services (Nursing), Ministry of Health, P.O. box 7272, Kampala, Uganda - Tel: +256 (0) 772 343 029 - E-mail: chotomargret@yahoo.com / Margaret.chota@health. go. u g 145. Mr. William DADA, Local Council V. Chairman, Koboigo -Tel: 0712 313 245 146. Dr Alfred DzuWALE, District Health Officer, Koboko District Health Office, P.O. Box 1, Koboko District, Uganda -Tel: +256 (0) 772 515 222 - E-mail: driwalealfred@yahoo.co.uk 147. Major Baker DDUDU, Resident District Commissioner, Adjumani District, Box 01, Uganda - Tel: +256 (0) 772 409 184 148. Mr. Moses ECHAT, Assistant, Oyam DLC P.O. Box 30 Loro, Uganda - Tel: +256 (0) 772 688 984 - E-mail: mosesechat@yahoo.com 149. Mr. Eria EMURWON, District Onchocerciasis Coordinator, P.O. Box 916, MBale - Tel: 0782 36 I I 6 I - Email: eriaemurwon@.vahoo.co.uk 150. Mr. George EWAI, Ag. Resident District Commissioner, Nebbi, Uganda - Tel: +256 (0) 782 320 921 151 Mr. Rashid Govule IYIGA, District Chairman (LC 5 Chairman), Agro Economist, P.O. Box Yumbe - Tel: 0772 479 009 - Email: )umbedistrict@)zahoo.com 152. Mr. Jalan Martin GWOKTO, CAO's Office Arua District Local Government, P.O. Box 1 Arua, Uganda - Tel: +256 (0) 772 460 408 - E-mail: martingwokto@yahoo.com 153. Mr. Nickson N. KABUYE, DEP RDC Bushenyi, Office of the President, Bushenyi District, Uganda - Tel: +256 (0) 772 683 98 1 I 07 52 I 0701 - E-mail: nickabuye@),ahoo.com 154. Mr. Paul KAGWA, Ministry of Health, Kampala, Uganda- E-mail: paulkagwa@yahoo.com 155. Mr. Sam Passy KHAUKFIA, Vice Chairman MBale district Local Government - Tel: 0782 335 346 156. Dr Abbas KAKEMBO, Ministry of Health Focal Person for Human African Trypanosomiasis (HAT) Control Programme, Vector Control Division, P.O. Box 1661, Kampala, Uganda - Tel: +256 (0) 772951169 - E-mail: kakemboabbas@yahoo.com 157. Mr. Bayeye KAMARA, Resident District Commissioner Sironko, Resident District Commissioner Sironko District, Uganda -East Africa - Tel: 0772 520 239 - E-mail: kamarabayeeye@yahoo.com 158. Mr. Kankonge KAMBARAGE, Resident District Commissioner (RDC), Kabarole, Uganda - Tel: +256 (0)772 443 459 159. Mr James KATAMANYWA, DVCO/DOC, Kyenjojo District, P.O. Box 1002, Kyenjojo - Tel 0772 351 661 - Email: katamanywa@yahoo.com 160. Dr Dan KYAMANYWA, Dishict Health Officer, Medical Doctor, P.O. Box 2, Kibaale, Uganda -Tel: +256 (0) 772 490345 - E-mail: dkyamanywa@yahoo.co.uk JAFI5.4 Page 3 I l6l. Mr. Melichiadis KAZWEMGYE, LCV chairperson, Ibanda District Local Government, P.O Box 388, Ibanda, Uganda -Tel: +256 (0) 772 449 953 162. Mr. Tom Luroni LAKWO, Entomologist, National Onchocerciais Control Programme (NOCP) Secretariat, Ministry of Health, P.O. Box 1661, Kampala, Uganda - Tel: (256) 414348-332 - Fax:(256) 414348-339 -Mobile: (256)772 438-3ll -E-mail:tlakwo2OOl@yahoo.com 163. Dr Peter LANGI, Programme Manager, Guinea Worm Eradication Programme, Ministry of Health, P.O. Box 7272, Kampala, Uganda - Tel: +256 414 235492 I +256 777 553314 - E- mail : ugwepmoh@ahoo.co.uk 164. Mr Hakiri LAURIANO, DVCO/DOC, District Health Office, Kanungu district, P.O. Box 130, Kanungu -Tel: 0772 561 661- Email: laurianohakiri@yahoo.com 165. Dr Jackie MABWEIBJANO, Mulago Hospital, Kampala, Uganda dr iackiemabweiiano@hotuatLsalq E-mail: 166. Mr. Tawaha MAGARA, Ministry of Foreign Affairs, Kampala, Uganda E-mail: magara@gmail.com 167 . Mr. Mukasa Joseph MAIRA, Chief Administrative Officer, Kabale District Local Government, P.O. Box 5, Kabale, Uganda - Tel: +256 (0) 486 22335 (Official) I +256 (0) 772 408 464 (Personal) - E-mail: caokdlg@yahoo.corn - official / ios-maira@yahoo.com - personal 168. Ms. Florence MANIA, District records Officer for CAO Moyo, Moyo District Local Government CAO Office, Uganda - Tel: +256 (0) 772 526 353 - E-mail: fomania@yahoo.com 169. Mr. Norbert MAO, Chairman, P.O. Box 2, Gulu District, Uganda - Tel: +256 (0) 772 885 688 - E-mail : mpmao(@yahoo.cogr 170. Ms Philemon MATEKE, District Chairman, Uganda l7l. Mr. Gabril K. MATWALE, Ministry of Health, Vector Control Division, P.O. Box 1661, Kampala, Uganda - Tel: (256) 414 251927 - E-mail: gkmatwale@vcdmoh.go.ug 172. Mr. Seruga MATOVU, Media Center, Kampala, Uganda - E-mail: cseruga@mediacenter.go.ug 173. Mr. Andrew MAWEJJE, Mbale Dishict Local Government CAO's Office, P.O. Box 984 Mbale, Uganda - Tel: +256 (0) 772 301 899 - E-mail: mawejjeandrew@gmail.com 174. Mr. Emmy Patrice MBAHA, District Health Officer, P.O. Box 50, Kisoro, Uganda -Tel: +256 (0) 772 650 616 - E-mail: mbahap@yahoo.co.uk / e-mbaha@yahoo.com 175. Mrs. Zakia MUGABA, National Onchocerciasis Control Programme (NOCP), Vector Control Division, Ministryof Health, Plot l5 Bombo Road, P.O. Box 1661, Kampala, Uganda-Tel: (256) 414 348-332 - Fax: (256) 4r4 348-339 - Mobile (256) 772-508600 I (256) 752-508600 I (256) 702-508600 - E-mail: zakieashitu@yahoo.co.uk ; zakiaenator@gmail.com 176. Mr William MUGAYO, District Onchocerciasis Coordinator, Vector Control Officer, Masindi Disfrict Local Government, P.O. Box 67 Masindi - Tel: 0772 688 408 - E-mail: muqavow@qmail.com 177. Mr. Frank MUGISHA, District Onchocerciasis Coordinater, Vector Control Officer, Ibanda District, Uganda - +256 (0)773 l8l 805 - E-mail: mugie02@yahoo.com JAF15.4 Page 32 178. Mr. Michael MUGISHA, District Chairperson, P.O. Box 38, Fort Portal, Kabarole, Uganda - Tel: +256 (0) 772 2468319 - E-mail: cmankdle@yahoo.co.uk 179. Mr. Richard MUHENDA, CAO, Kyenjojo District Local Government CAO's Office, Human Resource Division, Uganda -Tel: +256 (0) 772 862 652 180. Ms. Florence MUHUMUZA, Ministry of Health, P.O. Box 7272, Kampala, Uganda - Tel: +256 (0) 7 8 249 2445 - E -mail : kem babazifl orene i@yahoo. com l8l. Mr. Musana MLINENE, UPF, Kampala, Uganda - E-mail: ihnmusana@yahoo.corn 182. Mr. Edward MUSINGYE, District Chairperson, Kamwenge District Local Government, P.O Box 1408, Kamwenge, Ugana Tel: +256 (0) 772 590 025 E-mail eddiemusinqve@vahoo.com 183. Mr. Joshua MUTAMBI, MTTI, Kampala, Uganda - E-mail: imutambi com 184. Mr. Johnson MUTIINGWANDA, CAO - Chief Administrative Office, P.O 250. Kasese District, Uganda -Tel: +256 (0) 112 386 614 - E-mail: mutunaj@vahoo.com 185. Mrs Flavia NABWIRE, Assistant Chief Administrative Officer, ACAO Hoima District local Government, P.O.Box 2 Hoima,Uganda - Tel: 0777 466 709 I 0712 266 210 - E-mail: nabwire- flavia@yahoo.com 186. Mr Longino NDYANABO, District Chairman, Teacher Principal - Tel: 0772 310 290 187. Mr. Mathias NDIFIINA, Principal Assistant Secretary (PAS), Bushenyi Local Government, P.O. Box I Bushenyi -Tel: +256 (0) 774 315 314 188. Mr Henry NALYANYA, Deputy RDC - MBale, RDC'soffice,P.O. Box 984 Mbale - Tel: 0782 235 153 - Email: nal],ahenry@hotmail.com 189. Dr Aidah NANKINGA, Senior Medical Officer, P.O. Box I Bushenyi Local Government , Uganda -Tel: +256 (0) 753 840 553 - E-mail: aidahnamkinga@yahoo.com 190. Dr Joseph NSUBUGA, TV Technician, State House, P.O. box 11, Entebbe, Uganda - Tel +2s6 (0) 7722489801 19l. Mr. Frank NTAHO, Chief Administrative Officer, P.O. box 1408 Kamwenge, Uganda - Tel +256 (0) 772 684 sos 192. Mr. John Semafara NTIBIRINGEIRWA, Resident District Commissioner, Oyam District, P.O. Box 30, Loro, Oyam, Uganda Tel: +256 (0) 775 253 718 E-mail: semafaraj ohn@yahoo. co. uk 193. Mr. Cox Apuuli NYAKAIRU, Resident District Commissioner, P.O. Box 5, Kabale, Uganda Tel +256 (0) 772 52r 8tt I +2s6 (0) 702 s21 8l I 194. Ms. Esther NYAKATO, Ministry of Health, Kampala, Uganda - E-mail: nyaesk@lahoo.com 195. Dr Patrick ODONG OLWEDO, District Health Officer, Amuru District Local Government, P.O. Box 1074, Gulu, Uganda - +256 772 840 732 - E-mail: p-odong@yahoo.com / dho.amuru@yahoo.com a : JAFI5.4 Page 33 196. Dr Ambrose Ninston ONAPA, Programme Manager, NTD Control Programmed, c/o Vector Control Divisions, Ministry of Health, P.O. Box 70108, Kampala, Uganda - Tel: +256 (0) 414 343 414 I +256 (0) 772 497 180 - E-mail: kzibale I @yahoo.co.uk 197. Mr Ronald OCAATRE, Ag District Health Officer, District Health Educator P.O. Box I Arua, - Tel: 0777 466 709 10712 266 210 E-mail: ddhsarua@yahoo.co.uk (office) or romiria_9@yahoo.co. uk (personal) 198. Mr. Gregory OCEN, Principal Health lnspector/District Health Officer, Oyam District Local Government, Box 30, Loro, Oyam Tel: +256 (0) 772 910 157 E-mail; gre qoryocen@-vahoo. com 199. Mr Richard ODOKONYERO, Logistics Officer - NTD Control Programme, Ministry of Health, Vector Control Division, P.O. BOX 1661, Kampala - Tel: 0775 323 247 - Email: odokonyerorichard2006@yahoo.co. uk 2OO. Mr. Sam Vasco OGENRWOTH, Chief Administration Officer (CAO), Civil Servant, Sironko District Local Government, Uganda Tel: +256 (0) 782 674 5l I E-mail: o genworthsam @yhaqs.sam 201 Mr. Nicholas OGWENG, District Onchocerciasis Coordinator, Medical Entomologist NTD Coordinator, DHO Office Box l, Moyo, Uganda - Tel: +256 772 543 588 - E-mail: nicholasog@vahoo.com 202. Dr Joa OKECH OJONY, Medical Doctor, District Health Office Kabarole, P.O. Box 38 Fort Portal - Fax: 256 483 423 043 - Tel: 0772 482 106 - Email: ioaokech(@hElmail.sqm or ddns. kabarole@health. go.ug 203. Dr Jimmy OPIGO, Moyo District Health Services, P.O. Box 1, Moyo, Nganda, Uganda - Tel +25 6 7 7 2 9 62 60 1 - E-mail : opi goj immy@ g.mail.com 204. Mr. Ariong OSIKOL, ISO-OP, Kampala, Uganda - E-mail: sosikol@yahoo.co.uk 205. Mr. Geoffrey OTTO, Vector Control Officer, Oyam, D.L.G., P.O. 30, Loro, Oyam, Uganda - Tel: +256 (0) 782 516 597 - E-mail: geoff972@gmail.com 206. Mr. Cons OWOO, District Oncho Coordinator, District Health Office, P.O. Box 60, Gulu - Tel 07 7 2 5 19 041 - E-mail : owooconstantino@yahoo.com. u g 207 . Mr. Eramu PASCAL, Internal Affairs, Kampala, Uganda - E-mail: eramupascal@yahoo.com 208. Dr Francis RUNUMI, Commissioner Health Services/Planning , Medical Doctor, Ministry of Health, P.O. Box 7272,Kampala, Uganda -Tel: +256 (0) 782 303 247- E-mail: 209. Dr Joseph RUYOMGA, Medical Doctor, District Health Officer, Hoima District Local Government - Tel: 0772 611 467 - Email: ruyojoseph@hotmail.com 210. Mr. Christopher RUZAZA, District Onchocerciasis, Vector Control Officer -Tel: +256 (0) 772 681 884 2ll. Dr Stephen SEBUDDE, District Health Officer, P.O. Box 130 Kamungu District Local Government - Tel: 0772900138 - Email: drsebuddes@doctor.com I 212. Mr. Erasmus SSEMPLA, Kampala, Uganda - E-mail: esempala@,vahoo.co.uk JAF15.4 Page 34 213. Mrs. Rose TAZIO Rulito, District LCV, Adjumani District Local Government, P. O. Box 2, Uganda -Tel: +256 (0) 772 898 009 214. Mr. Wayo Protazius Bashaija TIGUzuHWAYO, Resident District Commissioner, Office of the President, RDC Ibanda, P.O. Box l, Ibanda -Tel:0772 699 990 215. Mr. Gabriel TIBUHWA, District Health Educator, Kasese District Health Office, P.O. Box 250, Kasese, Uganda -Tel: +256 772 605 938 - E-mail: tibugab@yahoo.com 216. Mrs. Rose TIRIDRI, Principal Assistant Health Educationist, Health Promotion & Education, Ministry of Health, P.O. Box 7272, Kampala, Uganda - Tel: +256 (0) 772 501705 - E-mail: tirid irose@yahoo.corn 211. Mr. Ephraim TTIKESIGA, District Onchocerciaisis Coordinator, Medical Entomology Unit Health Department, P.O. Box 38 Fort Portal District - Tel: 0772 561933- E-mail: etukesiga@yahoo.com 218. Mr. George TUMUSTIABE, Senior Clinical Officer, Kamwenge district local governmemt, P.O. Box 1408 Kamwenge - Tel: 0772 626 863 - E-mail: tumushabeg@yahoo.com 220. Mr. Silver TURYAHIKAYO, Asst CAO, P.O. Box 1, Kanungu, Uganda - Tel: +256(0) 103 861 620 - E-mail: sturgahika),o@yahoo.com 221 Mr. Safari Makacha TURYAHIKAYO, LCV Kanungu District, Uganda - +256 (0) 782 163 653 222. Mr James TURYEIMUKA, DVCOIDOC, District Health Office, Kabale District, P.O. Box 1002, Kyenjojo - Fax: 0486 422 190 - Tel: 0486 422 512 - Email: jturyeimuka@yahoo.com 223. Mr. Christopher TWEBAZE, District Oncho Coordinator, Kibaale District Local Government, Directorate of Health Services, P.O. 21, Karunguza, Uganda - Te: +256 (0) 772 697 905 - E- mail : Twebaze-chris@yahoo.com 224. Ms. Alice VUCIRI, Ag. District Health Officer, District Health Office, Adjumani District Local Government, P.O. Box 145, Adjumani, Uganda - Tel: +256 (0) 772 510857 I +256 (0) 755 260 9 46 - E-mail: alicemandera@yahoo.com 225. Mr. Primo VLI-NNY, Assistant District Onchocerciasis Coordinator, Mbale District Health Office, P.O. Box 904 Mbale, Uganda - Tel: +256 (0) 7122'76357 I +256 (0) 782 472 145 -E- mail: anzi2003 @yahoo.com 226. Dr Peter WAKOUBA, District Health Officer, Bududa District Local Government P.O. Box 292,Uganda - Tel: +256 (0) 782 308 719 -E-mail: pwakouba@yahoo.com 227. Mr Joseph WAMANI, DOC/District Vector Control Officer, Kamwenge District, P.O. Box 1408 Kamwenge -Tel:0772 368 682 - E-mail: wamanii@.yahoo.com 228. Mr. John WAPOKRA, Chairman L.C.5, Box l, Nebbi, Uganda - +256 (0) 772994 153 - E- mail: wapojohn@yahoo.com 219. Dr P. TURYAGUMA, Ministry of Health, Kampala, Uganda pturyaguma@yahoo.co.uk 229. Ms. H. WEGOSASA, Ministry of Health, Kampala, Uganda hwegosasa@hotmail.com E-mail a E-mail: 'l JAFI5.4 Page 35 230. Mr. Sylvester WANJUSI-WASIEBA, President District Commissioner, Resident District Commissioner (RDC),P.O.317, Mbale, Bududa district, Uganda - Tel: 0782 179 393 - Email: wanj uziwas ieba@yahoo. com 231. Mr. Edirisa WANGWANYI, lnterpreter, Oncho Focal person, Bufumbo Subcountry, Mbale district, -Tel:0752 816 481 I 0782 815 481 - Email: wangwanyiedirisa@yahoo.com 232. Mr. Charles WALIMBWA, Chairperson, P.O. Box 916, Mbale -Tel:0782 - 755 565 233. Dr Gideon Simiyu WAMASEBU, District Health Office Manafiva, P.O. Box 916, MBale - Tel 0772 642 431 - Email: gideonwamusebu@yahoo.com 234. Ms. Jennipher WATSEMWA, Medical officer, P.O. Box 11020, Nakaseke, Uganda - tel: +256 (0) 772 482 7ss 235. Mr. Tibugyenda WILSON, Chief Administrative Officer, Ibanda District Local Government, P.O. Box 388, Ibanda, Uganda -Tel: +256 (0) 172 566 I l0 AA/SDD 16.12.2008 JAFI5.4 Page 36 JOINT ACTION FORUM Office of the Chairman JOTNT ACTION FORUM Fourteenth session Kampala (Uganda). 8-l I December 2008 Annex 2 African Programme for Onchocerciasis Control (APOC) Programme africain de lutte contre I'onchocercose JAF-FAC FORUM D'ACTION COMMTINE Bureau du Pr6sident JAF14.2 Revision 2 PROVISIONAL AGENDA Opening 1. Opening of the session 2. Election of Officers 3. Adoption of Agenda 4. Reflections of the Committee of Sponsoring Agencies Progress 5. Progress Report of the World Health Organization 6. Country reports on treatment coverage, capacity building to empower communities and strengthen health systems, and on government contributions Closed session 7 . Closed session of Ministers of Health, donors and NGDOs Activities 8. Other important activities(i) Report of the NGDO Coordination Group for Onchocerciasis Control(ii) Report of the Technical Consultative Committee (TCC)(iii) Sustainability of CDTI by Governments: Review of implementation of plans(iv) Elimination of transmission of Onchocerciasis in Africa - Study in Mali and Senegal - Study in Kaduna State, Nigeria - Report and recommendations of the Uganda Onchocerciasis Elimination Committee (UOEC)(v) Report of the Final Evaluation of the Special lntervention Zones (SIZ) of the former OCP Research 9. Operational research and MACROFIL(i) Macrofil(ii) Health lmpact Assessment of APOC operations Finance 10. Audit report 1 1. Addendum to PAB 2008 - 2015 12. Plan of Action and Budget for 2009 13. Financing of the African Programme for Onchocerciasis Control (APOC) 14. Pledging of Donor contributions Former OCP Countries and MDSC 15. Information on activities in the ex-OCP countries and the Multi-Disease Surveillance Centre (MDSC), Ouagadougou 16. Date and place of the fifteenth session , Final Communiqu6 17. Final Communiqu6 I 8. Closure of the fourteenth session JAFI5.4 Page 37 DrR/APOC/18.1 1.2008 t , t ,